Jazz Pharmaceuticals (JAZZ) 10-Q 7 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	JAZZ
Entity Registrant Name	Jazz Pharmaceuticals plc
Entity Central Index Key	1232524
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		61,066,950

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$782,603	$684,042
Accounts receivable, net of allowances	189,682	186,371
Inventories	30,692	30,037
Prepaid expenses	27,614	12,800
Deferred tax assets, net	50,822	48,440
Other current assets	21,522	21,322
Assets held for sale	0	32,833
Total current assets	1,102,935	1,015,845
Property and equipment, net	71,283	58,363
Intangible assets, net	1,284,308	1,437,435
Goodwill	654,470	702,713
Deferred tax assets, net, non-current	74,185	75,494
Deferred financing costs	31,223	33,174
Other non-current assets	19,189	15,931
Total assets	3,237,593	3,338,955
Current liabilities:
Accounts payable	27,317	25,126
Accrued liabilities	146,975	164,091
Current portion of long-term debt	9,388	9,428
Income taxes payable	26,334	7,588
Deferred tax liability, net	9,430	9,430
Deferred revenue	1,138	1,138
Total current liabilities	220,582	216,801
Deferred revenue, non-current	4,215	4,499
Long-term debt, less current portion	1,334,661	1,333,000
Deferred tax liability, net, non-current	327,683	375,054
Other non-current liabilities	45,122	38,393
Commitments and contingencies
Jazz Pharmaceuticals plc shareholders' equity
Ordinary shares	6	6
Non-voting euro deferred shares	55	55
Capital redemption reserve	471	471
Additional paid-in capital	1,488,262	1,458,005
Accumulated other comprehensive loss	-278,584	-122,097
Retained earnings	95,066	34,704
Total Jazz Pharmaceuticals plc shareholders’ equity	1,305,276	1,371,144
Noncontrolling interests	54	64
Total shareholders’ equity	1,305,330	1,371,208
Total liabilities and shareholders’ equity	$3,237,593	$3,338,955

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Product sales, net	$307,035	$244,986
Royalties and contract revenues	2,268	1,933
Total revenues	309,303	246,919
Operating expenses:
Cost of product sales (excluding amortization of intangible assets)	28,298	30,924
Selling, general and administrative	112,388	106,363
Research and development	27,181	18,109
Acquired in-process research and development	0	127,000
Intangible asset amortization	24,677	31,182
Total operating expenses	192,544	313,578
Income (loss) from operations	116,759	-66,659
Interest expense, net	-16,245	-10,076
Foreign currency gain	2,245	123
Income (loss) before income tax provision	102,759	-76,612
Income tax provision	32,059	17,027
Net income (loss)	70,700	-93,639
Net loss attributable to noncontrolling interests, net of tax	0	-989
Net income (loss) attributable to Jazz Pharmaceuticals plc	$70,700	($92,650)
Net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share:
Basic (in dollars per share)	$1.16	($1.58)
Diluted (in dollars per share)	$1.12	($1.58)
Weighted-average ordinary shares used in calculating net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share:
Basic (in shares)	60,803	58,526
Diluted (in shares)	62,964	58,526

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Comprehensive Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Net income (loss)	$70,700	($93,639)
Other comprehensive income (loss):
Foreign currency translation adjustments	-156,497	15,016
Other comprehensive income (loss)	-156,497	15,016
Total comprehensive loss	-85,797	-78,623
Comprehensive loss attributable to noncontrolling interests, net of tax	-10	-712
Comprehensive loss attributable to Jazz Pharmaceuticals plc	($85,787)	($77,911)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements Of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Operating activities
Net income (loss)	$70,700	($93,639)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Intangible asset amortization	24,677	31,182
Share-based compensation	20,819	13,815
Depreciation	2,232	1,309
Acquired in-process research and development	0	127,000
Loss on disposal of property and equipment	8	2
Excess tax benefit from share-based compensation	-10,635	-5,777
Acquisition accounting inventory fair value step-up adjustments	0	8,022
Deferred income taxes	-9,261	-4,378
Provision for losses on accounts receivable and inventory	426	813
Other non-cash transactions	632	1,868
Changes in assets and liabilities:
Accounts receivable	-4,769	-16,014
Inventories	-1,842	-3,071
Prepaid expenses and other current assets	-15,670	4,357
Other long-term assets	-3,278	-1,545
Accounts payable	3,303	8,579
Accrued liabilities	-17,485	927
Income taxes payable	30,163	5,757
Deferred revenue	-285	-273
Contingent consideration	0	-14,900
Other non-current liabilities	6,820	4,689
Net cash provided by operating activities	96,555	68,723
Investing activities
Net proceeds from sale of business	32,703	0
Purchases of property and equipment	-14,410	-3,527
Acquisitions, net of cash acquired	0	-828,676
Acquisition of in-process research and development	0	-125,000
Net cash provided by (used in) investing activities	18,293	-957,203
Financing activities
Payment of employee withholding taxes related to share-based awards	-14,778	-9,363
Share repurchases	-10,338	0
Repayments of long-term debt	-2,284	-2,299
Proceeds from employee equity incentive plans and exercise of warrants	13,504	21,467
Excess tax benefit from share-based compensation	10,635	5,777
Net proceeds from issuance of debt	0	636,355
Acquisition of noncontrolling interests	0	-119,175
Payment of contingent consideration	0	-35,100
Net cash provided by (used in) financing activities	-3,261	497,662
Effect of exchange rates on cash and cash equivalents	-13,026	188
Net increase (decrease) in cash and cash equivalents	98,561	-390,630
Cash and cash equivalents, at beginning of period	684,042	636,504
Cash and cash equivalents, at end of period	$782,603	$245,874

The_Company_and_Summary_of_Sig

The Company and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
The Company and Summary of Significant Accounting Policies	The Company and Summary of Significant Accounting Policies
	Jazz Pharmaceuticals plc, a public limited company formed under the laws of Ireland, is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. We have a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, we market Xyrem® (sodium oxybate) oral solution and Erwinaze® (asparaginase Erwinia chrysanthemi) in the United States, and market Erwinase® and Defitelio® (defibrotide) in Europe and other countries outside the United States. Our strategy is to create shareholder value by:
	•	Growing sales of the existing products in our portfolio, including by identifying new growth opportunities;
	•	Acquiring additional differentiated products that are on the market or product candidates that are in late-stage development; and
	•	Pursuing focused development of a pipeline of post-discovery differentiated product candidates.
	Throughout this report, unless otherwise indicated or the context otherwise requires, all references to “Jazz Pharmaceuticals,” “the registrant,” “we,” “us,” and “our” refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries. Throughout this report, all references to “ordinary shares” refer to Jazz Pharmaceuticals plc’s ordinary shares.
	Basis of Presentation
	These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission, or SEC, for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or GAAP, can be condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our annual consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2014.
	In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015, for any other interim period or for any future period.
	These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our subsidiaries and intercompany transactions and balances have been eliminated. We record noncontrolling interests in our condensed consolidated financial statements which represent the ownership interest of minority shareholders in the equity of Gentium S.p.A., or Gentium. Our condensed consolidated financial statements include the results of operations of businesses we have acquired from the date of each acquisition for the applicable reporting periods.
	Significant Risks and Uncertainties
	Our financial results remain significantly influenced by sales of Xyrem. In the three months ended March 31, 2015, net product sales of Xyrem were $212.7 million, which represented 69.3% of total net product sales. Our ability to maintain or increase sales of Xyrem in its approved indications is subject to a number of risks and uncertainties, including the potential introduction of generic competition or an alternative sodium oxybate product that competes with Xyrem, changed or increased regulatory restrictions, continued acceptance of Xyrem by physicians and patients and restrictive conditions for reimbursement required by, and the availability of reimbursement from, third party payors. Five abbreviated new drug applications, or ANDAs, have been filed with the U.S. Food and Drug Administration, or FDA, by third parties seeking to market generic versions of Xyrem. We have initiated lawsuits against all five third parties, and the litigation proceedings are ongoing. We cannot predict the timing or outcome of these proceedings. Although no trial date has been set in any of the ANDA suits, we anticipate that trial on some of the patents in the case against the first ANDA filer, Roxane Laboratories, Inc., or Roxane, could occur as early as the fourth quarter of 2015. In addition, certain of the ANDA filers are challenging the validity of our patents covering the distribution system for Xyrem by filing petitions for inter partes review, or IPR, by the Patent Trial and Appeal Board, or PTAB, of the U.S. Patent and Trademark Office. Furthermore, in April 2015, a hedge fund (acting with affiliated entities and individuals and proceeding under the name of the Coalition for Affordable Drugs III LLC) filed an IPR petition challenging the validity of one of our Xyrem distribution patents that is already the subject of a previously-filed IPR petition. The PTAB has not yet determined whether to institute proceedings with respect to the petitions for IPR. We cannot predict whether PTAB will institute any of the petitioned IPR proceedings, whether additional post-grant patent review challenges will be filed by any of the ANDA filers or any other entity, the outcome of any IPR or other proceeding if instituted, or the impact any IPR or other proceeding might have on ongoing ANDA litigation proceedings or other aspects of our Xyrem business. We expect that the approval of an ANDA that results in the launch of a generic version of Xyrem, or the approval and launch of other sodium oxybate products that compete with Xyrem, would have a material adverse effect on our business, financial condition, results of operations and growth prospects.
	We are in the process of implementing the necessary systems, processes, procedures and activities to transition to the final risk evaluation and mitigation strategy, or REMS, for Xyrem approved by the FDA in late February 2015. While we expect to implement the Xyrem REMS by late August 2015 and to submit ongoing assessments, in each case as set forth in the FDA’s Xyrem REMS approval notice, we cannot guarantee that we will be able to do so in a timely manner, that our implementation of the approved Xyrem REMS will meet FDA requirements, that the assessments will be satisfactory to the FDA, or that the Xyrem REMS will satisfy FDA’s expectations in their anticipated evaluation of the Xyrem REMS on an ongoing basis. Any failure to transition to the Xyrem REMS in a timely manner and to the satisfaction of the FDA or to comply with the REMS obligations could negatively affect sales of Xyrem, result in additional costs and expenses for us, and/or take a significant amount of time, any of which could materially and adversely affect our business, financial condition, results of operations and growth prospects. In addition, we cannot predict whether the FDA will seek to require or ultimately require modifications to the Xyrem REMS, including with respect to the distribution system, or seek to otherwise impose or ultimately impose additional requirements to the Xyrem REMS, or the potential timing, terms or propriety thereof. Any such modifications or additional requirements could potentially make it more difficult or expensive for us to distribute Xyrem, make it easier for future generic competitors, and/or negatively affect sales of Xyrem.
	We also expect to continue to face pressure to develop a single shared REMS with potential generic competitors for Xyrem or to license or share intellectual property pertinent to the Xyrem REMS, which is the subject of multiple issued patents, or elements of the Xyrem REMS, with generic competitors. In January 2014, the FDA held an initial meeting with us and the then-current sodium oxybate ANDA applicants to facilitate the development of a single shared REMS for sodium oxybate. The parties have had regular interactions with respect to developing a single shared REMS since the initial meeting, and we expect the interactions to continue. If we do not develop a single shared REMS or license or share intellectual property pertinent to our Xyrem REMS with a generic competitor within a time frame or on terms that the FDA considers acceptable, the FDA may assert that its waiver authority permits it to allow the generic competitor to market a generic drug with a separate REMS that includes different, but comparable, elements to assure safe use, than those in our approved Xyrem REMS. We cannot predict the outcome or impact on our business of any future action that we may take with respect to the development of a single shared REMS for sodium oxybate, licensing or sharing intellectual property pertinent to our Xyrem REMS, or the FDA’s response to a certification that a third party had been unable to obtain a license. In addition, the Federal Trade Commission, other governmental authorities or others could claim or determine that we are using the Xyrem REMS in an anticompetitive manner (including in light of the FDA’s statement in the Xyrem REMS approval notice that the Xyrem REMS could be used in an anticompetitive manner inconsistent with applicable provisions of the Federal Food, Drug and Cosmetic Act) or have engaged in other anticompetitive practices.
	Sales of our second largest product, Erwinaze, continue to grow. In the three months ended March 31, 2015, net product sales of Erwinaze/Erwinase were $50.4 million which represented 16.4% of total net product sales. We seek to maintain and increase sales of Erwinaze, as well as to make Erwinaze more widely available, through ongoing sales and marketing and research and development activities. However, our ability to successfully and sustainably maintain or grow sales of Erwinaze is subject to a number of risks and uncertainties, including the limited population of patients with acute lymphoblastic leukemia, or ALL, and the incidence of hypersensitivity reactions to E. coli-derived asparaginase within that population, our ability to obtain clinical data on the use of Erwinaze in young adults age 18 to 39 with ALL who are hypersensitive to E. coli-derived asparaginase, particularly in light of our recent decision to terminate a clinical trial in this patient population based on an inability to enroll patients, as well as our need to apply for and receive marketing authorizations, through the European Union’s mutual recognition procedure or otherwise, in certain additional countries so we can launch promotional efforts in those countries. Another significant challenge to our ability to maintain current sales levels and to increase sales is our need to avoid supply interruptions of Erwinaze due to capacity constraints, production delays, quality challenges or other manufacturing difficulties. We have limited inventory of Erwinaze, which puts us at significant risk of not being able to meet product demand. Erwinaze is licensed from and manufactured by a single source, which was Public Health England, or PHE, through March 31, 2015. PHE has advised us that as of April 1, 2015, the facility at which Erwinaze is manufactured was transferred to Porton BioPharma Limited, a limited liability company that is wholly-owned by the U.K. Secretary of State for Health, or PBL. We were informed that all of the staff employed in the manufacture and management of Erwinaze have transferred into PBL, and we are now working with PBL on matters related to Erwinaze supply. The current manufacturing capacity for Erwinaze is nearly completely absorbed by demand for the product. As a consequence of constrained manufacturing capacity, we have had an extremely limited ability to build an excess level of product inventory that could be used to absorb disruptions to supply resulting from any quality or other issues. If we continue to be subject to capacity constraints or experience quality or other manufacturing challenges in the future, we may be unable to build a desired excess level of product inventory, and our ability to supply the market may be compromised. Although we are taking steps to improve the Erwinaze manufacturing process, if our ongoing efforts are not successful, we could experience additional Erwinaze supply interruptions in the future, which could have a material adverse effect on our sales of and revenues from Erwinaze and limit our potential future maintenance and growth of the market for this product. In addition, while we continue to work with the manufacturer of Erwinaze to evaluate potential steps to expand production capacity to increase the supply of Erwinaze over the longer term to address worldwide demand, our ability to maintain or increase sales of Erwinaze may be limited by our ability to obtain a sufficient supply of the product.
	In furtherance of our growth strategy, we have made a significant investment in Defitelio/defibrotide. We added the product to our portfolio as a result of our acquisition of Gentium that closed in January 2014, or the Gentium Acquisition, and secured worldwide rights to the product by acquiring rights to defibrotide in the Americas in August 2014. Our ability to realize the anticipated benefits from this investment is subject to a number of risks and uncertainties, including our ability to successfully maintain or grow sales of Defitelio in Europe, or obtain marketing approval in other countries, including the United States, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. We expect to continue to launch Defitelio in additional European countries on a rolling basis in 2015 and are in the process of making pricing and reimbursement submissions with respect to Defitelio, and discussing them with regulatory authorities, in those European countries where Defitelio is not yet launched, including in countries where pricing and reimbursement approvals are required for launch. A key challenge to our success in maintaining or growing sales of Defitelio in Europe is our ability to obtain appropriate pricing and reimbursement approvals in those European countries where Defitelio is not yet launched. If we experience delays or unforeseen difficulties in obtaining favorable pricing and reimbursement approvals, planned launches in the affected countries would be delayed, or, if we are unable to ultimately obtain favorable pricing and reimbursement approvals in countries that represent significant markets, especially where a country’s reimbursed price influences other countries, our growth prospects in Europe could be negatively affected.
	We are also engaged in activities related to the potential approval of defibrotide in the United States. We initiated a rolling submission of a new drug application, or NDA, to the FDA for defibrotide for the treatment of severe hepatic veno-occlusive disease, or VOD, in December 2014 and expect to complete the submission in mid-2015. We do not expect to be required to complete any additional clinical trials prior to completion of the NDA submission for defibrotide in the United States. Even if we are able to complete the NDA submission as planned, we cannot predict whether our NDA will be approved in a timely manner, if at all. It is possible that the FDA may ask an Oncologic Drugs Advisory Committee, or ODAC, which provides the FDA with independent expert advice and recommendations, to review our NDA. The ODAC may recommend against approval of our NDA, may recommend conditioning approval on our conducting one or more potentially time-consuming and costly clinical trials to provide supporting data either before approval or as a post-marketing commitment, or may recommend more narrow or restricted labeling than we expect to propose. We also face other challenges that could impact the anticipated value of Defitelio/defibrotide, including the limited size of the population of patients who undergo hematopoietic stem cell transplantation, or HSCT, therapy and develop severe VOD, the need to establish U.S. pricing and reimbursement support for the product in the event we are able to obtain U.S. marketing approval for defibrotide, the possibility that we may be required to conduct time-consuming and costly clinical trials as a condition of any U.S. marketing approval for the product, the lack of experience of U.S. physicians in diagnosing and treating VOD, and challenges to our ability to develop the product for indications in addition to the treatment of severe VOD. If sales of Defitelio/defibrotide do not reach the levels we expect, our anticipated revenue from the product would be negatively affected, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
	In addition to risks specifically related to Xyrem, Erwinaze and Defitelio/defibrotide, we are subject to other challenges and risks specific to our business, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including: the challenges of protecting and enhancing our intellectual property rights; delays or problems in the supply or manufacture of our products, particularly with respect to certain products as to which we maintain limited inventories, including products for which our supply demands are growing, and our dependence on single source suppliers to continue to meet our ongoing commercial demand or our requirements for clinical trial supplies; the need to obtain and maintain appropriate pricing and reimbursement for our products in an increasingly challenging environment due to, among other things, the attention being paid to healthcare cost containment and other austerity measures in the United States and worldwide, including the need to obtain and maintain reimbursement for Xyrem in the United States in an environment in which we are subject to increasingly restrictive conditions for reimbursement required by third party payors; and the challenges of compliance with the requirements of the FDA, the U.S. Drug Enforcement Administration, or DEA, and non-U.S. regulatory agencies, including with respect to product labeling, requirements for distribution, obtaining sufficient DEA quotas where needed, marketing and promotional activities, adverse event reporting and product recalls or withdrawals.
	Other risks and uncertainties related to our ability to execute on our strategy include: the challenges of achieving and maintaining commercial success of our products, such as obtaining sustained acceptance and support of our products by patients, physicians and payors; the risks and costs associated with business combination or product or product candidate acquisition transactions, such as the challenges inherent in the integration of acquired businesses with our historic business, the increase in geographic dispersion among our centers of operation, taking on the operation of a manufacturing plant as a result of the Gentium Acquisition and the risks that we may acquire unanticipated liabilities along with acquired businesses or otherwise fail to realize the anticipated benefits (commercial or otherwise) from such transactions; the difficulty and uncertainty of pharmaceutical product development, including the timing thereof, and the uncertainty of clinical success, such as the risk that results from preclinical studies and/or early clinical trials may not be predictive of results obtained in later and larger clinical trials planned or anticipated to be conducted for our product candidates; the inherent uncertainty associated with the regulatory approval process, especially as we continue to undertake increased activities and make growing investment in our product pipeline development projects; our potential inability to identify and acquire, in-license or develop additional products or product candidates to grow our business; and possible restrictions on our ability and flexibility to pursue certain future corporate development and other opportunities as a result of our substantial outstanding debt obligations, which increased significantly in 2014.
	Concentrations of Risk
	Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities and issuers of investments to the extent recorded on the balance sheet.
	We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the United States, and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of March 31, 2015, five customers accounted for 87% of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliate CuraScript, Inc., or Express Scripts, which accounted for 69% of gross accounts receivable and IDIS Limited, or IDIS, which accounted for 9% of gross accounts receivable.  As of December 31, 2014, five customers accounted for 86% of gross accounts receivable, including Express Scripts, which accounted for 66% of gross accounts receivable and IDIS, which accounted for 11% of gross accounts receivable.
	We depend on single source suppliers and manufacturers for each of our products, product candidates and their active pharmaceutical ingredients.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.
	Net Income (Loss) Attributable to Jazz Pharmaceuticals plc per Ordinary Share
	Basic net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share is based on the weighted-average number of ordinary shares outstanding. Diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding.
	Basic and diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share were computed as follows (in thousands, except per share amounts):
		Three Months Ended
		March 31,
		2015			2014
	Numerator:
	Net income (loss) attributable to Jazz Pharmaceuticals plc	$	70,700		$	(92,650	)
	Denominator:
	Weighted-average ordinary shares used in calculating net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share - basic	60,803			58,526
	Dilutive effect of employee equity incentive and purchase plans	2,161			—
	Weighted-average ordinary shares used in calculating net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share - diluted	62,964			58,526
	Net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share:
	Basic	$	1.16		$	(1.58	)
	Diluted	$	1.12		$	(1.58	)
	For the three months ended March 31, 2014, potentially dilutive ordinary shares from employee equity incentive and purchase plans and warrants were not included in the diluted net loss attributable to Jazz Pharmaceuticals plc per ordinary share because the inclusion of such shares would have an anti-dilutive effect.
	Potentially dilutive ordinary shares from our employee equity incentive and purchase plans, warrants and exchangeable senior notes are determined by applying the treasury stock method to the assumed exercise of share options and warrants, the assumed vesting of outstanding restricted stock units, or RSUs, the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP, and the assumed issuance of ordinary shares upon exchange of our exchangeable senior notes. The potential issue of approximately 2.9 million ordinary shares issuable upon exchange of our exchangeable senior notes had no effect on diluted net income attributable to Jazz Pharmaceuticals plc per ordinary share because the average price of our ordinary shares for the three months ended March 31, 2015 did not exceed the effective exchange price of $199.77 per ordinary share.
	The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):
		Three Months Ended
		March 31,
		2015		2014
	1.875% exchangeable senior notes due 2021	2,878		—
	Options to purchase ordinary shares and RSUs	1,322		5,491
	Warrants to purchase ordinary shares	—		1,257
	Ordinary shares under ESPP	—		141
	Recent Accounting Pronouncements
	In April 2015, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2015-03, “Interest - Imputation of Interest”, or ASU No. 2015-03. ASU No. 2015-03 requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the debt liability instead of as an asset. ASU No. 2015-03 does not affect the recognition and measurement guidance for debt issuance costs. ASU No. 2015-03 will be effective for us beginning January 1, 2016 and requires retrospective application. ASU-2015-03 will represent a change in accounting principle in 2016, the year of adoption. We are currently evaluating the impact of ASU 2015-03 on the presentation of our consolidated financial statements.
	In April 2015, the FASB issued ASU No. 2015-05, “Intangibles-Goodwill and Other-Internal-Use Software”, or ASU No. 2015-05. ASU No. 2015-05 provides guidance on whether a cloud computing arrangement contains a software license to be accounted for as internal-use software to assist in the evaluation of the accounting for fees paid by a customer in the arrangement. ASU No. 2015-05 will be effective for us beginning January 1, 2016 and may be applied either prospectively to new cloud computing arrangements or retrospectively. We are currently evaluating the impact of ASU 2015-05 on our consolidated financial statements.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers”, or ASU No. 2014-09, which states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this, an entity will need to identify the contract with a customer; identify the separate performance obligations in the contract; determine the transaction price; allocate the transaction price to the separate performance obligations in the contract; and recognize revenue when (or as) the entity satisfies each performance obligation. ASU No. 2014-09 will be effective for us beginning January 1, 2017 and can be adopted on a full retrospective basis or on a modified retrospective basis. We are currently assessing our approach to the adoption of this standard and the impact on our results of operations and financial position.

Disposition

Disposition	3 Months Ended
	Mar. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Disposition	Disposition
	On March 20, 2015, we completed the sale of certain products that we originally acquired as part of our acquisition of EUSA Pharma Inc. and the related business. Pursuant to the agreement for this sale, the purchase price was $34.0 million, subject to pre- and post-closing purchase price adjustments. We received approximately $33 million in cash after purchase price adjustments were made prior to the closing.
	We recognized a loss on disposal of $0.2 million in the three months ended March 31, 2015 within selling, general and administrative expenses in our condensed consolidated statements of operations. The related assets met the assets held for sale criteria and were reclassified to assets held for sale as of December 31, 2014. Goodwill was allocated to these assets using the relative fair value method. We have determined that the disposition of these assets did not qualify for reporting as a discontinued operation since the sale does not represent a strategic shift that has or will have a major effect on our operations and financial results.

Fair_Value_Measurement

Fair Value Measurement	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement
	Cash and cash equivalents consisted of the following (in thousands):
		31-Mar-15
		Amortized		Gross		Gross		Estimated		Cash and Cash Equivalents
		Cost		Unrealized		Unrealized		Fair Value
				Gains		Losses
	Cash	$	187,491	$	—	$	—	$	187,491	$	187,491
	Time deposits	595,112		—		—		595,112		595,112
	Totals	$	782,603	$	—	$	—	$	782,603	$	782,603
		31-Dec-14
		Amortized		Gross		Gross		Estimated		Cash and
		Cost		Unrealized		Unrealized		Fair Value		Cash
				Gains		Losses				Equivalents
	Cash	$	338,262	$	—	$	—	$	338,262	$	338,262
	Time deposits	345,780		—		—		345,780		345,780
	Totals	$	684,042	$	—	$	—	$	684,042	$	684,042
	Cash equivalents are considered available-for-sale securities. We use the specific-identification method for calculating realized gains and losses on securities sold and include them in interest expense, net in the condensed consolidated statements of operations.
	The following table summarizes, by major security type, our available-for-sale securities as of March 31, 2015 and December 31, 2014 that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands):
		31-Mar-15				31-Dec-14
		Significant Other		Total		Significant		Total
		Observable		Estimated		Other		Estimated
		Inputs		Fair Value		Observable		Fair Value
		(Level 2)				Inputs
						(Level 2)
	Time deposits	$	595,112	$	595,112	$	345,780	$	345,780
	As of March 31, 2015, our available-for-sale securities included time deposits which were measured at fair value using Level 2 inputs and their carrying values were approximately equal to their fair values. Level 2 inputs, obtained from various third party data providers, represent quoted prices for similar assets in active markets, or these inputs were derived from observable market data, or if not directly observable, were derived from or corroborated by other observable market data. There were no transfers between the different levels of the fair value hierarchy in 2015 or in 2014.
	As of March 31, 2015, the estimated fair value of the $893.1 million principal amount of our term loans was approximately $893 million and the carrying amount was $888.6 million. The fair value was determined using quotes from the administrative agent of our credit facility that are based on the bid/ask prices of our term loans (Level 2). As of March 31, 2015, the estimated fair value of our exchangeable senior notes was approximately $669 million. The fair value of the exchangeable senior notes was estimated using quoted market prices obtained from brokers (Level 2). The fair value of other borrowings approximates book value based on the borrowing rates currently available for variable rate loans (Level 2).
	As of December 31, 2014, assets measured at fair value on a non-recurring basis subsequent to initial recognition included assets classified as held for sale on the condensed consolidated balance sheet. The carrying amount of $32.8 million for assets held for sale was equal to estimated fair value, which was based on the sales price agreed less costs to sell, and represented a Level 3 input. We completed the sale of these assets on March 20, 2015.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories
	Inventories consisted of the following (in thousands):
		March 31,		December 31,
		2015		2014
	Raw materials	$	2,358	$	3,570
	Work in process	13,319		9,870
	Finished goods	15,015		16,597
	Total inventories	$	30,692	$	30,037

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets
	The gross carrying amount of goodwill was as follows (in thousands):
	Balance at December 31, 2014	$	702,713
	Foreign exchange	(48,243		)
	Balance at March 31, 2015	$	654,470
	The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):
		March 31, 2015									December 31, 2014
		Remaining		Gross		Accumulated			Net Book		Gross		Accumulated			Net Book
		Weighted-		Carrying		Amortization			Value		Carrying		Amortization			Value
		Average Useful		Amount							Amount
		Life
		(In years)
	Acquired developed technologies	12.7		$	1,317,675	$	(256,258	)	$	1,061,417	$	1,450,606	$	(259,889	)	$	1,190,717
	Manufacturing contracts	2.8		11,616		(3,458		)	8,158		13,012		(3,060		)	9,952
	Trademarks	—		2,880		(2,880		)	—		2,914		(2,896		)	18
	Total finite-lived intangible assets			1,332,171		(262,596		)	1,069,575		1,466,532		(265,845		)	1,200,687
	Acquired IPR&D assets			214,733		—			214,733		236,748		—			236,748
	Total intangible assets			$	1,546,904	$	(262,596	)	$	1,284,308	$	1,703,280	$	(265,845	)	$	1,437,435
	The decrease in the gross carrying amount of intangible assets as of March 31, 2015 compared to December 31, 2014 reflects the negative impact of foreign currency translation adjustments which is primarily due to the strengthening of the U.S. dollar against the Euro.
	The assumptions and estimates used to determine future cash flows and remaining useful lives of our intangible and other long-lived assets are complex and subjective. They can be affected by various factors, including external factors, such as industry and economic trends, and internal factors such as changes in our business strategy and our forecasts for specific product lines.
	Based on finite-lived intangible assets recorded as of March 31, 2015, and assuming the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands):
	Year Ending December 31,	Estimated
		Amortization
		Expense
	2015 (remainder)	$	70,507
	2016	90,688
	2017	90,688
	2018	87,168
	2019	86,952
	Thereafter	643,572
	Total	$	1,069,575

Certain_Balance_Sheet_Items

Certain Balance Sheet Items	3 Months Ended
	Mar. 31, 2015
Certain Balance Sheet Items [Abstract]
Certain Balance Sheet Items	Certain Balance Sheet Items
	Property and equipment consisted of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Construction-in-progress	$	49,447		$	37,145
	Computer software	12,460			10,634
	Computer equipment	8,754			7,670
	Leasehold improvements	8,191			7,931
	Machinery and equipment	5,804			6,408
	Furniture and fixtures	2,171			2,220
	Land and buildings	1,380			1,547
	Subtotal	88,207			73,555
	Less accumulated depreciation and amortization	(16,924		)	(15,192		)
	Property and equipment, net	$	71,283		$	58,363
	Accrued liabilities consisted of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Rebates and other sales deductions	$	58,003		$	51,899
	Employee compensation and benefits	27,707			46,143
	Sales returns reserve	10,777			14,039
	Accrued interest	7,637			10,327
	Royalties	7,158			7,964
	Accrued construction-in-progress	6,050			4,931
	Professional fees	3,726			3,295
	Other	25,917			25,493
	Total accrued liabilities	$	146,975		$	164,091

Debt

Debt	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt	Debt
	As of March 31, 2015, the principal balance of our outstanding debt was $1.5 billion, which included $893.1 million of outstanding secured debt under a credit agreement that we entered into in June 2012 and subsequently amended in June 2013 and January 2014, which we refer to as our credit agreement, and $575.0 million of outstanding debt under our 1.875% exchangeable senior notes due 2021, or the 2021 Notes, which were issued in August 2014.
	The following table summarizes the carrying amount of our indebtedness (in thousands):
		March 31,			December 31,
		2015			2014
	1.875% exchangeable senior notes due 2021	$	575,000		$	575,000
	Unamortized discount on 1.875% exchangeable senior notes due 2021	(120,985		)	(124,735		)
	1.875% exchangeable senior notes due 2021, net	454,015			450,265
	Term loans	888,550			890,479
	Other borrowings	1,484			1,684
	Total debt	1,344,049			1,342,428
	Less current portion	9,388			9,428
	Total long-term debt	$	1,334,661		$	1,333,000
	The 2021 Notes were issued by Jazz Investments I Limited, or the Issuer, a 100%-owned finance subsidiary of Jazz Pharmaceuticals plc. The Issuer’s obligations under the 2021 Notes are fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc. No subsidiary of Jazz Pharmaceuticals plc guaranteed the 2021 Notes. Subject to certain local law restrictions on payment of dividends, among other things, and potential negative tax consequences, we are not aware of any significant restrictions on the ability of Jazz Pharmaceuticals plc to obtain funds from the Issuer or Jazz Pharmaceuticals plc’s other subsidiaries by dividend or loan, or any legal or economic restrictions on the ability of the Issuer or Jazz Pharmaceuticals plc’s other subsidiaries to transfer funds to Jazz Pharmaceuticals plc in the form of cash dividends, loans or advances. There is no assurance that in the future such restrictions will not be adopted.
	As of March 31, 2015, the carrying value of the equity component of the 2021 Notes, net of equity issuance costs, was $126.9 million.
	The credit agreement, which provides for term loans and a revolving credit facility, contains a financial covenant that requires Jazz Pharmaceuticals plc and its restricted subsidiaries to maintain a maximum secured leverage ratio. We were, as of March 31, 2015, and are currently in compliance with this financial covenant. As of March 31, 2015, the interest rate on the term loans was 3.25% and the effective interest rate was 4.1%. As of March 31, 2015, we had undrawn revolving credit facilities totaling $425.0 million of which $1.1 million was committed for an outstanding letter of credit.
	Maturities
	Scheduled maturities with respect to our long-term debt are as follows (in thousands):
	Year Ending December 31,	Scheduled Long-Term Debt Maturities
	2015 (remainder)	$	7,106
	2016	9,391
	2017	9,396
	2018	868,452
	2019	101
	Thereafter	575,134
	Total	$	1,469,580

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Indemnification
	In the normal course of business, we enter into agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. Our exposure under these agreements is unknown because it involves future claims that may be made but have not yet been made against us. To date, we have not paid any claims or been required to defend any action related to these indemnification obligations.
	We have agreed to indemnify our executive officers, directors and certain other employees for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments we could be required to make under the indemnification obligations is unlimited; however, we maintain insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage and the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly, we did not recognize any liabilities relating to these obligations as of March 31, 2015 and December 31, 2014. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.
	Lease and Other Commitments
	We have noncancelable operating leases for our office buildings and we are obligated to make payments under noncancelable operating leases for automobiles used by our sales force. Future minimum lease payments under our noncancelable operating leases at March 31, 2015 were as follows (in thousands):
	Year Ending December 31,	Lease
		Payments
	2015 (remainder)	$	7,422
	2016	7,609
	2017	7,137
	2018	7,831
	2019	7,145
	Thereafter	73,265
	Total	$	110,409
	In January 2015, we entered into an agreement to lease office space located in Palo Alto, California in a building to be constructed by the landlord. We expect to occupy this office space by the end of 2017. The lease has a term of 12 years from the commencement date as defined in the lease agreement and we have an option to extend the term of the lease twice for a period of five years each. We are obligated to make lease payments totaling approximately $88 million over the initial term of the lease. In connection with this lease, the landlord is providing a tenant improvement allowance for the costs associated with the design, development and construction of tenant improvements for the leased facility. We are obligated to fund all costs incurred in excess of the tenant improvement allowance. The scope of the planned tenant improvements do not qualify as “normal tenant improvements” under the lease accounting guidance. Accordingly, for accounting purposes, we have concluded we are the deemed owner of the building during the construction period. As of March 31, 2015, we recorded project construction costs of $1.0 million incurred by the landlord as construction-in-progress in property and equipment, net and a corresponding financing obligation in other non-current liabilities in our condensed consolidated balance sheets. We will increase the asset and financing obligation as additional building costs are incurred by the landlord during the construction period. Rent expense of $0.4 million associated with the ground lease during construction was recognized in the condensed consolidated statement of operations in the three months ended March 31, 2015.
	As of March 31, 2015, we had $27.4 million of noncancelable purchase commitments due within one year, primarily related to agreements with third party manufacturers.
	In April 2015, we amended an existing operating sublease for office space in Palo Alto, California for additional office space and extended the term of this sublease to December 2017. As a result of the amendment, we are obligated to make additional lease payments of approximately $10 million. We also obtained an option to extend the term of the sublease twice for a period of one year each.
	Legal Proceedings
	We are involved in several legal proceedings, including the following matters:
	Xyrem ANDA Matters: On October 18, 2010, we received a notice of Paragraph IV Patent Certification, or Paragraph IV Certification, from Roxane that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem (sodium oxybate) oral solution. Roxane’s initial notice alleged that all five patents then listed for Xyrem in the FDA’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations,” or Orange Book, on the date of the notice are invalid, unenforceable or not infringed by Roxane’s proposed generic product. On November 22, 2010, we filed a lawsuit against Roxane in response to Roxane’s initial notice in the U.S. District Court for the District of New Jersey, or the District Court, seeking a permanent injunction to prevent Roxane from introducing a generic version of Xyrem that would infringe our patents. In accordance with the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Act, as a result of our having filed a timely lawsuit against Roxane, FDA approval of Roxane’s ANDA was stayed for 30 months, or until April 18, 2013. That stay has expired. Additional patents covering Xyrem were issued between December 2010 and December 2012, and, after receiving Paragraph IV Certification notices from Roxane, we filed additional lawsuits against Roxane on February 4, 2011, May 2, 2011, October 26, 2012 and December 5, 2012 to include these additional patents in the litigation. All of the lawsuits filed against Roxane between 2010 and 2012 have been consolidated by the District Court into a single case, or the Roxane consolidated case, alleging that 10 of our patents covering Xyrem are or will be infringed by Roxane’s ANDA and seeking a permanent injunction to prevent Roxane from launching a generic version of Xyrem that would infringe these patents.
	In December 2013, the District Court permitted Roxane to amend its answer in the Roxane consolidated case to allege additional equitable defenses, and the parties were given additional time for discovery on those new defenses. In addition, in March 2014, the District Court granted our motion to bifurcate and stay the portion of the Roxane consolidated case regarding patents related to the distribution system for Xyrem. Although no trial date has been scheduled, based on the District Court’s current schedule, we anticipate that trial on the patents in the Roxane consolidated case that are not subject to the stay could occur as early as the fourth quarter of 2015. We do not have any estimate of a possible trial date for trial on the patents in the Roxane consolidated case that are currently subject to the stay. The actual timing of events in this litigation may be significantly earlier or later than we currently anticipate, and we cannot predict the specific timing or outcome of events in this litigation.
	On April 1, 2014 and January 15, 2015, we received additional notices of Paragraph IV Certification from Roxane regarding newly issued patents for Xyrem listed in the Orange Book. On February 20, 2015, we filed a new lawsuit against Roxane in the District Court, alleging that three of our patents covering Xyrem are infringed or will be infringed by Roxane’s ANDA and seeking a permanent injunction to prevent Roxane from introducing a generic version of Xyrem that would infringe these patents. On April 20, 2015, Roxane moved to dismiss claims involving our patent covering a part of the Xyrem label that instructs prescribers on adjusting the dose of Xyrem when it is being co-administered with divalproex sodium (also known as valproate or valproic acid) on the grounds that this patent does not cover patentable subject matter. We cannot predict the timing or outcome of events in this matter or its impact on the Roxane consolidated case.
	On December 10, 2012, December 12, 2012 and August 8, 2013, we received notices of Paragraph IV Certification from Amneal Pharmaceuticals, LLC, or Amneal, that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. On January 18, 2013 and September 12, 2013, we filed lawsuits against Amneal in the District Court, alleging that nine of our patents covering Xyrem are infringed or will be infringed by Amneal’s ANDA and seeking a permanent injunction to prevent Amneal from introducing a generic version of Xyrem that would infringe these patents. These lawsuits against Amneal were consolidated by the District Court on November 6, 2013.
	On November 21, 2013 and November 24, 2013, we received notices of Paragraph IV Certification from Par Pharmaceutical, Inc., or Par, that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. On December 27, 2013, we filed a lawsuit against Par in the District Court, alleging that 13 of our patents covering Xyrem are infringed or will be infringed by Par’s ANDA and seeking a permanent injunction to prevent Par from introducing a generic version of Xyrem that would infringe these patents.
	In April 2014, Amneal asked the District Court to consolidate its case with the Par case, stating that both cases would proceed on the schedule for the Par case. The District Court granted this request in May 2014. The order consolidating the cases provides that Amneal’s 30-month stay period will be extended to coincide with the date of Par’s 30-month stay period. As a result, FDA’s approval of both Amneal’s and Par’s ANDAs is stayed until the earlier of (i) May 20, 2016, or (ii) a District Court decision finding that the identified patents are invalid, unenforceable or not infringed. We cannot predict the timing or outcome of events in the Amneal/Par consolidated case or their impact on other ongoing proceedings with Amneal or Par as described below.
	On April 7, 2014 and January 19, 2015, we received additional notices of Paragraph IV Certification from Amneal regarding newly issued patents for Xyrem listed in the Orange Book. On May 20, 2014 and February 6, 2015, we filed additional lawsuits against Amneal in the District Court, alleging that four of our patents covering Xyrem are infringed or will be infringed by Amneal’s ANDA and seeking a permanent injunction to prevent Amneal from introducing a generic version of Xyrem that would infringe these patents. We cannot predict the timing or outcome of events in these matters or their impact on other ongoing proceedings with Amneal.
	On July 3, 2014, August 6, 2014 and November 25, 2014, we received additional notices of Paragraph IV Certification from Par regarding newly issued patents for Xyrem listed in the Orange Book. We filed additional lawsuits against Par in the District Court on August 15, 2014, October 2, 2014 and January 8, 2015, alleging that three of our patents covering Xyrem are infringed or will be infringed by Par’s ANDA and seeking a permanent injunction to prevent Par from introducing a generic version of Xyrem that would infringe these patents. We cannot predict the timing or outcome of events in these matters or their impact on other ongoing proceedings with Par.
	On June 4, 2014, we received a notice of Paragraph IV Certification from Ranbaxy Laboratories Limited, or Ranbaxy, that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. On June 6, 2014, we received a notice of an amended Paragraph IV Certification from Ranbaxy. On July 15, 2014, we filed a lawsuit against Ranbaxy in the District Court, alleging that 14 of our patents covering Xyrem are infringed or will be infringed by Ranbaxy’s ANDA and seeking a permanent injunction to prevent Ranbaxy from introducing a generic version of Xyrem that will infringe these patents. On August 20, 2014 and December 1, 2014, we received additional notices of Paragraph IV Certification from Ranbaxy regarding newly issued patents for Xyrem listed in the Orange Book. On October 2, 2014 and January 9, 2015, we filed additional lawsuits against Ranbaxy in the District Court, alleging that two of our patents covering Xyrem are infringed or will be infringed by Ranbaxy’s ANDA and seeking a permanent injunction to prevent Ranbaxy from introducing a generic version of Xyrem that would infringe these patents. We cannot predict the timing or outcome of events in these matters or their impact on other ongoing proceedings with Ranbaxy.
	On October 30, 2014, we received a notice of Paragraph IV Certification from Watson Laboratories, Inc., or Watson, that it has submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. On December 11, 2014, we filed a lawsuit against Watson in the District Court, alleging that 15 of our patents covering Xyrem are or will be infringed by Watson’s ANDA and seeking a permanent injunction to prevent Watson from introducing a generic version of Xyrem that would infringe these patents. On March 23, 2015, Watson moved to dismiss the portion of the case based on our Orange Book-listed patents covering the distribution system for Xyrem on the grounds that these patents do not cover patentable subject matter. We cannot predict the timing or outcome of events in this litigation.
	In January 2015, Amneal, Ranbaxy and Watson proposed the consolidation of their respective cases and a consolidated schedule to the District Court, while Par sought its own proposed schedule with the District Court, notwithstanding the prior consolidation of portions of the Par and Amneal cases. In April 2015, the District Court issued an order that consolidated all then-pending lawsuits against Amneal, Par, Ranbaxy and Watson into one case, the Amneal/Par/Ranbaxy/Watson consolidated case. Under a related scheduling order issued in March 2015, the District Court would hold a Markman hearing for the Amneal/Par/Ranbaxy/Watson consolidated case no earlier than January 2016. We cannot predict the timing or outcome of events in the Amneal/Par/Ranbaxy/Watson consolidated case or their impact on other ongoing proceedings with any individual ANDA filer, including Roxane, Amneal, Par, Ranbaxy or Watson.
	On March 23, 2015, March 24, 2015, March 26, 2015 and April 16, 2015, we received an additional notice of Paragraph IV Certification from each of Par, Amneal, Ranbaxy and Roxane, respectively, regarding a newly issued method of treatment patent for Xyrem listed in the Orange Book.
	Xyrem Post-Grant Patent Review Matters: Between June and August 2014, petitions seeking covered business method, or CBM, post-grant patent review by the PTAB were filed by certain of the ANDA filers with respect to the validity of six of our patents related to the distribution system for Xyrem. In the fall of 2014, we filed preliminary responses to the petitions in which, among other things, we asserted that the challenged patents should not be subject to CBM review. In early 2015, the PTAB issued decisions denying institution of CBM review for all of these petitions.
	In January 2015, petitions for IPR were filed by certain of the ANDA filers with respect to the validity of six of our patents related to the distribution system for Xyrem. In April 2015, we filed preliminary responses to these petitions, opposing the petitions and stating reasons that review should not be granted.  In addition, in April 2015, a hedge fund (acting with affiliated entities and individuals and proceeding under the name of the Coalition for Affordable Drugs III LLC) filed an IPR petition challenging the validity of one of our Xyrem distribution patents that is already the subject of a previously-filed IPR petition. The PTAB has not yet determined whether to institute proceedings with respect to these petitions for IPR. We cannot predict whether PTAB will institute any of the petitioned IPR proceedings, whether additional post-grant patent review challenges will be filed by any of the ANDA filers or any other entity, the outcome of any IPR or other proceeding if instituted, or the impact any IPR or other proceeding might have on ongoing ANDA litigation proceedings.
	FazaClo ANDA Matters: Azur Pharma Public Limited Company, or Azur Pharma (prior to the business combination between Jazz Pharmaceuticals, Inc. and Azur Pharma) received notices of Paragraph IV Certifications from three generics manufacturers, Barr Laboratories, Inc., or Barr, Novel Laboratories, Inc., or Novel, and Mylan Pharmaceuticals, Inc., or Mylan, indicating that ANDAs had been filed with the FDA requesting approval to market generic versions of FazaClo® (clozapine, USP) LD orally disintegrating clozapine tablets. Azur Pharma and CIMA Labs Inc., or CIMA, a subsidiary of Teva Pharmaceutical Industries Limited, or Teva, our licensor and the entity whose drug-delivery technology is incorporated into FazaClo LD, filed a lawsuit in response to each certification claiming infringement based on such certification against Barr on August 21, 2008, against Novel on November 25, 2008 and against Mylan on July 23, 2010. Each case was filed in the U.S. District Court for the District of Delaware, or the Delaware Court. On July 6, 2011, CIMA, Azur Pharma and Teva, which had acquired Barr, entered into an agreement settling the patent litigation and Azur Pharma granted a sublicense to an affiliate of Teva of Azur Pharma’s rights to have manufactured, market and sell a generic version of both FazaClo LD and FazaClo HD, as well as an option for supply of authorized generic product. The sublicense for FazaClo LD commenced in July 2012, and the sublicense for FazaClo HD will commence in May 2015. Teva exercised its option for supply of an authorized generic product for FazaClo LD and launched the authorized generic product at the end of August 2012. Teva has also exercised its option for supply of an authorized generic product for FazaClo HD. The Novel and Mylan matters had been stayed pending reexamination of the patents in the lawsuits. In September 2013 and January 2014, reexamination certificates were issued for the two patents-in-suit, and the patentability of the claims of the patents confirmed. The Delaware Court lifted the stay of litigation in the two cases in March 2014. On December 19, 2014, we and CIMA entered into an agreement with Novel settling the patent litigation against Novel and we granted Novel a sublicense to manufacture, market and sell a generic version of FazaClo LD and, if applicable, FazaClo HD. The sublicense will commence on May 1, 2017, or earlier upon the occurrence of certain events. Trial in the Mylan case is currently set for the third quarter of 2015, but we cannot predict the specific timing or outcome of this litigation.
	Cutler Matter: On October 19, 2011, Dr. Neal Cutler, one of the original owners of FazaClo, filed a complaint against Azur Pharma and one of its subsidiaries, as well as Avanir Pharmaceuticals, Inc., or Avanir, in the California Superior Court in the County of Los Angeles, or the Superior Court. The complaint alleges that Azur Pharma and its subsidiary breached certain contractual obligations. Azur Pharma acquired rights to FazaClo from Avanir in 2007. The complaint alleges that as part of the acquisition of FazaClo, Azur Pharma’s subsidiary agreed to assume certain contingent payment obligations to Dr. Cutler. The complaint further alleges that certain contingent payments are due because revenue thresholds have been achieved, entitling Dr. Cutler to a $10.5 million and an additional $25.0 million contingent payment, plus unspecified punitive damages and attorneys’ fees. In March 2012, the Superior Court granted our petition to compel arbitration of the dispute in New York and stayed the Superior Court litigation. In July 2012, the arbitrator dismissed the arbitration on the grounds that the parties’ dispute falls outside of the scope of the arbitration clause in the applicable contract. That ruling was affirmed by the California Court of Appeal in January 2014, and the case was remanded to Superior Court for discovery and trial. Trial has been scheduled for October 2015. We cannot predict the specific timing or outcome of this litigation.
	Shareholder Litigation Matter: In January 2014, we became aware of a purported class action lawsuit filed in the U.S. District Court for the Southern District of New York in connection with the Gentium Acquisition.  The lawsuit named Gentium, each of the Gentium’s directors, us and our Italian subsidiary as defendants. The lawsuit alleged, among other things, that Gentium’s directors breached their fiduciary duties to Gentium’s shareholders in connection with the Gentium tender offer agreement that Gentium entered into with us and our Italian subsidiary valuing Gentium ordinary shares and American Depositary Shares at $57.00 per share, and that we and our Italian subsidiary violated Sections 14(e) and 20(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, by allegedly overseeing Gentium’s preparation of an allegedly false and misleading Section 14D-9 Solicitation/Recommendation Statement. On November 19, 2014, the plaintiff dismissed us and our Italian subsidiary from the lawsuit. On January 22, 2015, the entire lawsuit was dismissed with prejudice by the court.
	From time to time we are involved in legal proceedings arising in the ordinary course of business. We believe there is no other litigation pending that could have, individually or in the aggregate, a material adverse effect on our results of operations or financial condition.
	Other Contingencies
	We have not previously submitted pricing data for two radiopharmaceutical products, ProstaScint® (capromab pendetide) and Quadramet® (samarium sm 153 lexidronam injection), for Medicaid and the Public Health Service’s 340B drug pricing discount program.  We engaged in interactions with the Centers for Medicare and Medicaid Services, or CMS, and a trade group, the Council on Radionuclides and Radiopharmaceuticals, or CORAR, regarding the reporting of Medicaid pricing data and paying Medicaid rebates for radiopharmaceutical products.  For ProstaScint, we plan to begin making any required reports when CMS issues guidance on any requirements and reporting methodologies.  We sold Quadramet to a third party in December 2013, but have retained any liabilities related to sales of the product during prior periods.  In addition to the discussions with CMS as part of CORAR, we have had separate discussions with CMS directly regarding Quadramet.  We are currently unable to predict whether price reporting and rebates will be required for ProstaScint and Quadramet and, if so, for what period they will be required.  The initiation of any reporting of Medicaid pricing data for ProstaScint and Quadramet could result in retroactive 340B ceiling price liability for these two products as well as prospective 340B ceiling price obligations for ProstaScint. We are currently unable to reasonably estimate an amount or range of a potential contingent loss. Any material liability resulting from radiopharmaceutical price reporting would negatively impact our financial results.

Shareholders_Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders’ Equity
	The following tables present a reconciliation of our beginning and ending balances in shareholders’ equity for the three months ended March 31, 2015 and 2014, respectively (in thousands):
		Attributable to:
		Jazz Pharmaceuticals plc			Noncontrolling interests			Total Shareholders' Equity
	Shareholders' equity at January 1, 2015	$	1,371,144		$	64		$	1,371,208
	Issuance of ordinary shares in conjunction with employee equity incentive plans	13,504			—			13,504
	Employee withholding taxes related to share-based awards	(14,778		)	—			(14,778		)
	Share-based compensation	20,896			—			20,896
	Tax benefit from employee share options	10,635			—			10,635
	Shares repurchased	(10,338		)	—			(10,338		)
	Other comprehensive loss	(156,487		)	(10		)	(156,497		)
	Net income	70,700			—			70,700
	Shareholders' equity at March 31, 2015	$	1,305,276		$	54		$	1,305,330
		Attributable to:
		Jazz Pharmaceuticals plc			Noncontrolling interests			Total Shareholders' Equity
	Shareholders' equity at January 1, 2014	$	1,295,534		$	—		$	1,295,534
	Noncontrolling interests from the Gentium Acquisition	—			136,578			136,578
	Acquisition of noncontrolling interests	(924		)	(118,251		)	(119,175		)
	Issuance of ordinary shares in conjunction with employee equity incentive plans and warrant exercises	21,467			—			21,467
	Employee withholding taxes related to share-based awards	(9,363		)	—			(9,363		)
	Share-based compensation	14,313			—			14,313
	Tax benefit from employee share options	5,777			—			5,777
	Other comprehensive income	14,739			277			15,016
	Net loss	(92,650		)	(989		)	(93,639		)
	Shareholders' equity at March 31, 2014	$	1,248,893		$	17,615		$	1,266,508
	Share Repurchase Program
	In May 2013, our board of directors authorized a share repurchase program pursuant to which we may repurchase a number of ordinary shares having an aggregate repurchase price of up to $200 million, exclusive of any brokerage commissions. In the three months ended March 31, 2015, we spent a total of $10.3 million to purchase 0.1 million of our ordinary shares under the share repurchase program at an average total purchase price, including commissions, of $164.54 per share. All ordinary shares repurchased by us were canceled. As of March 31, 2015, the remaining amount authorized under the share repurchase program was $11.0 million.
	Accumulated Other Comprehensive Loss
	The components of accumulated other comprehensive loss attributable to Jazz Pharmaceuticals plc as of March 31, 2015 and December 31, 2014 were as follows (in thousands):
		Foreign			Total
		Currency			Accumulated
		Translation			Other
		Adjustments			Comprehensive
					Loss
	Balance at December 31, 2014	$	(122,097	)	$	(122,097	)
	Other comprehensive loss	(156,487		)	(156,487		)
	Balance at March 31, 2015	$	(278,584	)	$	(278,584	)
	In the three months ended March 31, 2015, other comprehensive loss reflects foreign currency translation adjustments which are primarily due to the strengthening of the U.S. dollar against the Euro.

Segment_and_Other_Information

Segment and Other Information	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segment and Other Information	Segment and Other Information
	Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker, or CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment which is the development and commercialization of meaningful pharmaceutical products that address unmet medical needs. The following table presents a summary of total revenues (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Xyrem® (sodium oxybate) oral solution	$	212,690		$	160,378
	Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi)	50,353			46,920
	Defitelio® (defibrotide)/defibrotide	17,363			12,209
	Prialt® (ziconotide) intrathecal infusion	6,764			4,309
	Psychiatry	9,093			9,866
	Other	10,772			11,304
	Product sales, net	307,035			244,986
	Royalties and contract revenues	2,268			1,933
	Total revenues	$	309,303		$	246,919
	The following table presents a summary of total revenues attributed to geographic sources (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	United States	$	269,247		$	214,956
	Europe	32,635			24,343
	All other	7,421			7,620
	Total revenues	$	309,303		$	246,919
	The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:
		Three Months Ended
		March 31,
		2015		2014
	Express Scripts	69	%	65	%
	Accredo Health Group, Inc.	13	%	15	%
	The following table presents total long-lived assets, consisting of property and equipment, by location (in thousands):
		March 31,			December 31,
		2015			2014
	Ireland	$	50,190		$	37,775
	United States	10,963			9,795
	Italy	7,767			8,462
	Other	2,363			2,331
	Total long-lived assets	$	71,283		$	58,363

ShareBased_Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation
	Share-based compensation expense related to share options, RSUs and grants under our ESPP was as follows (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Selling, general and administrative	$	16,639		$	11,175
	Research and development	3,485			2,459
	Cost of product sales	695			181
	Total share-based compensation expense, pre-tax	20,819			13,815
	Tax benefit from share-based compensation expense	(6,154		)	(4,286		)
	Total share-based compensation expense, net of tax	$	14,665		$	9,529
	Share Options
	The table below shows the number of shares underlying options granted to purchase our ordinary shares, the weighted-average assumptions used in the Black-Scholes option pricing model and the resulting weighted-average grant date fair value of share options granted:
		Three Months Ended
		March 31,
		2015			2014
	Shares underlying options granted (in thousands)	880			706
	Grant date fair value	$	57.49		$	63.08
	Black-Scholes option pricing model assumption information:
	Volatility	39		%	46		%
	Expected term (years)	4.2			4.3
	Range of risk-free rates	1.1-1.3%			1.1-1.2%
	Expected dividend yield	—		%	—		%
	Restricted Stock Units
	The table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted:
		Three Months Ended
		March 31,
		2015			2014
	RSUs granted (in thousands)	338			341
	Grant date fair value	$	174.56		$	165.61
	The fair value of RSUs is determined on the date of grant based on the market price of our ordinary shares on that date. The fair value of RSUs is recognized as expense ratably over the vesting period of four years.
	As of March 31, 2015, compensation cost not yet recognized related to unvested share options and RSUs was $98.8 million and $109.6 million, respectively, which is expected to be recognized over a weighted-average period of 2.7 years and 2.6 years, respectively.

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2015
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring
	In the fourth quarter of 2014, we incurred severance costs for terminated employees in connection with our decision to discontinue sales representative-led promotion of our psychiatry products starting in 2015. In addition, we initiated a restructuring plan related to the consolidation of our U.K. office locations and incurred costs of severance for terminated employees and facility closure costs in connection with this plan. The one-time termination benefits were recorded over the remaining service period where employees were required to stay through their termination date to receive the benefits. We recorded costs related to these one-time termination benefits of $0.4 million in the three months ended March 31, 2015 within selling, general and administrative expenses in our condensed consolidated statements of operations. Facility closure costs of $0.2 million incurred in the three months ended March 31, 2015 were recorded within selling, general and administrative expenses in our condensed consolidated statements of operations. As of March 31, 2015, we had incurred total termination benefit and facility closure costs of $2.2 million and $0.3 million, respectively, in connection with these plans. We do not expect to incur additional termination benefit or facility closure costs in 2015.
	The following table summarizes the amounts related to restructuring through March 31, 2015 (in thousands):
		Termination Benefits			Facility Closure Costs			Total
	Balance at December 31, 2014	$	1,823		$	118		$	1,941
	Costs incurred during the period	371			182			553
	Cash payments	(1,756		)	(117		)	(1,873		)
	Balance at March 31, 2015	$	438		$	183		$	621
	The balances as of March 31, 2015 and December 31, 2014 were included within accrued liabilities in our condensed consolidated balance sheets.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	Our income tax provision for the three months ended March 31, 2015 was $32.1 million compared to $17.0 million for the same period in 2014. Our effective tax rate for the three months ended March 31, 2015 was 31.2%. After adjusting the loss before income tax provision for the three months ended March 31, 2014 by excluding upfront and milestone payments of $127.0 million for rights to JZP-110, which were acquired by our subsidiary in a non-taxable jurisdiction, the effective tax rate on the resulting income before income tax provision for the three months ended March 31, 2014 was 33.8%. The decrease in the effective tax rate was primarily due to changes in income mix among the various jurisdictions in which we operate, the impact of originating tax credits and increased deductions available in relation to subsidiary equity. The effective tax rate for the three months ended March 31, 2015 was higher than the Irish statutory rate of 12.5% primarily due to income taxable at a rate higher than the Irish statutory rate, uncertain tax positions, current year losses in some jurisdictions for which no tax benefit is available and various expenses not deductible for tax purposes, partially offset by originating tax credits and deductions available in relation to subsidiary equity. We do not provide for Irish income taxes on undistributed earnings of our foreign operations that are intended to be indefinitely reinvested in our foreign subsidiaries.
	Our deferred tax assets are comprised primarily of U.S. federal and state net operating loss carryforwards and tax credit carryforwards, foreign net operating loss carryforwards and other temporary differences. We maintain a valuation allowance against certain U.S. state and foreign deferred tax assets. Each reporting period, we evaluate the need for a valuation allowance on our deferred tax assets by jurisdiction and adjust our estimates as more information becomes available.
	We are required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. As a result, we have established a liability for certain tax benefits which we judge may not be sustained upon examination. Our most significant tax jurisdictions are Ireland, the United States (both at the federal level and in various state jurisdictions), Italy and France. Because of our net operating loss carryforwards and tax credit carryforwards, substantially all of our tax years remain open to federal, state, and foreign tax examination. Certain of our subsidiaries are currently under examination by the French tax authorities for fiscal years 2012 and 2013 and by Italian tax authorities for fiscal year 2012. We do not anticipate that the amount of our existing liability for unrecognized tax benefits will significantly change within the next 12 months.

The_Company_and_Summary_of_Sig1

The Company and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission, or SEC, for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or GAAP, can be condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our annual consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2014.
	In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015, for any other interim period or for any future period.
	These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our subsidiaries and intercompany transactions and balances have been eliminated. We record noncontrolling interests in our condensed consolidated financial statements which represent the ownership interest of minority shareholders in the equity of Gentium S.p.A., or Gentium. Our condensed consolidated financial statements include the results of operations of businesses we have acquired from the date of each acquisition for the applicable reporting periods.
Significant Risks and Uncertainties	Significant Risks and Uncertainties
	Our financial results remain significantly influenced by sales of Xyrem. In the three months ended March 31, 2015, net product sales of Xyrem were $212.7 million, which represented 69.3% of total net product sales. Our ability to maintain or increase sales of Xyrem in its approved indications is subject to a number of risks and uncertainties, including the potential introduction of generic competition or an alternative sodium oxybate product that competes with Xyrem, changed or increased regulatory restrictions, continued acceptance of Xyrem by physicians and patients and restrictive conditions for reimbursement required by, and the availability of reimbursement from, third party payors. Five abbreviated new drug applications, or ANDAs, have been filed with the U.S. Food and Drug Administration, or FDA, by third parties seeking to market generic versions of Xyrem. We have initiated lawsuits against all five third parties, and the litigation proceedings are ongoing. We cannot predict the timing or outcome of these proceedings. Although no trial date has been set in any of the ANDA suits, we anticipate that trial on some of the patents in the case against the first ANDA filer, Roxane Laboratories, Inc., or Roxane, could occur as early as the fourth quarter of 2015. In addition, certain of the ANDA filers are challenging the validity of our patents covering the distribution system for Xyrem by filing petitions for inter partes review, or IPR, by the Patent Trial and Appeal Board, or PTAB, of the U.S. Patent and Trademark Office. Furthermore, in April 2015, a hedge fund (acting with affiliated entities and individuals and proceeding under the name of the Coalition for Affordable Drugs III LLC) filed an IPR petition challenging the validity of one of our Xyrem distribution patents that is already the subject of a previously-filed IPR petition. The PTAB has not yet determined whether to institute proceedings with respect to the petitions for IPR. We cannot predict whether PTAB will institute any of the petitioned IPR proceedings, whether additional post-grant patent review challenges will be filed by any of the ANDA filers or any other entity, the outcome of any IPR or other proceeding if instituted, or the impact any IPR or other proceeding might have on ongoing ANDA litigation proceedings or other aspects of our Xyrem business. We expect that the approval of an ANDA that results in the launch of a generic version of Xyrem, or the approval and launch of other sodium oxybate products that compete with Xyrem, would have a material adverse effect on our business, financial condition, results of operations and growth prospects.
	We are in the process of implementing the necessary systems, processes, procedures and activities to transition to the final risk evaluation and mitigation strategy, or REMS, for Xyrem approved by the FDA in late February 2015. While we expect to implement the Xyrem REMS by late August 2015 and to submit ongoing assessments, in each case as set forth in the FDA’s Xyrem REMS approval notice, we cannot guarantee that we will be able to do so in a timely manner, that our implementation of the approved Xyrem REMS will meet FDA requirements, that the assessments will be satisfactory to the FDA, or that the Xyrem REMS will satisfy FDA’s expectations in their anticipated evaluation of the Xyrem REMS on an ongoing basis. Any failure to transition to the Xyrem REMS in a timely manner and to the satisfaction of the FDA or to comply with the REMS obligations could negatively affect sales of Xyrem, result in additional costs and expenses for us, and/or take a significant amount of time, any of which could materially and adversely affect our business, financial condition, results of operations and growth prospects. In addition, we cannot predict whether the FDA will seek to require or ultimately require modifications to the Xyrem REMS, including with respect to the distribution system, or seek to otherwise impose or ultimately impose additional requirements to the Xyrem REMS, or the potential timing, terms or propriety thereof. Any such modifications or additional requirements could potentially make it more difficult or expensive for us to distribute Xyrem, make it easier for future generic competitors, and/or negatively affect sales of Xyrem.
	We also expect to continue to face pressure to develop a single shared REMS with potential generic competitors for Xyrem or to license or share intellectual property pertinent to the Xyrem REMS, which is the subject of multiple issued patents, or elements of the Xyrem REMS, with generic competitors. In January 2014, the FDA held an initial meeting with us and the then-current sodium oxybate ANDA applicants to facilitate the development of a single shared REMS for sodium oxybate. The parties have had regular interactions with respect to developing a single shared REMS since the initial meeting, and we expect the interactions to continue. If we do not develop a single shared REMS or license or share intellectual property pertinent to our Xyrem REMS with a generic competitor within a time frame or on terms that the FDA considers acceptable, the FDA may assert that its waiver authority permits it to allow the generic competitor to market a generic drug with a separate REMS that includes different, but comparable, elements to assure safe use, than those in our approved Xyrem REMS. We cannot predict the outcome or impact on our business of any future action that we may take with respect to the development of a single shared REMS for sodium oxybate, licensing or sharing intellectual property pertinent to our Xyrem REMS, or the FDA’s response to a certification that a third party had been unable to obtain a license. In addition, the Federal Trade Commission, other governmental authorities or others could claim or determine that we are using the Xyrem REMS in an anticompetitive manner (including in light of the FDA’s statement in the Xyrem REMS approval notice that the Xyrem REMS could be used in an anticompetitive manner inconsistent with applicable provisions of the Federal Food, Drug and Cosmetic Act) or have engaged in other anticompetitive practices.
	Sales of our second largest product, Erwinaze, continue to grow. In the three months ended March 31, 2015, net product sales of Erwinaze/Erwinase were $50.4 million which represented 16.4% of total net product sales. We seek to maintain and increase sales of Erwinaze, as well as to make Erwinaze more widely available, through ongoing sales and marketing and research and development activities. However, our ability to successfully and sustainably maintain or grow sales of Erwinaze is subject to a number of risks and uncertainties, including the limited population of patients with acute lymphoblastic leukemia, or ALL, and the incidence of hypersensitivity reactions to E. coli-derived asparaginase within that population, our ability to obtain clinical data on the use of Erwinaze in young adults age 18 to 39 with ALL who are hypersensitive to E. coli-derived asparaginase, particularly in light of our recent decision to terminate a clinical trial in this patient population based on an inability to enroll patients, as well as our need to apply for and receive marketing authorizations, through the European Union’s mutual recognition procedure or otherwise, in certain additional countries so we can launch promotional efforts in those countries. Another significant challenge to our ability to maintain current sales levels and to increase sales is our need to avoid supply interruptions of Erwinaze due to capacity constraints, production delays, quality challenges or other manufacturing difficulties. We have limited inventory of Erwinaze, which puts us at significant risk of not being able to meet product demand. Erwinaze is licensed from and manufactured by a single source, which was Public Health England, or PHE, through March 31, 2015. PHE has advised us that as of April 1, 2015, the facility at which Erwinaze is manufactured was transferred to Porton BioPharma Limited, a limited liability company that is wholly-owned by the U.K. Secretary of State for Health, or PBL. We were informed that all of the staff employed in the manufacture and management of Erwinaze have transferred into PBL, and we are now working with PBL on matters related to Erwinaze supply. The current manufacturing capacity for Erwinaze is nearly completely absorbed by demand for the product. As a consequence of constrained manufacturing capacity, we have had an extremely limited ability to build an excess level of product inventory that could be used to absorb disruptions to supply resulting from any quality or other issues. If we continue to be subject to capacity constraints or experience quality or other manufacturing challenges in the future, we may be unable to build a desired excess level of product inventory, and our ability to supply the market may be compromised. Although we are taking steps to improve the Erwinaze manufacturing process, if our ongoing efforts are not successful, we could experience additional Erwinaze supply interruptions in the future, which could have a material adverse effect on our sales of and revenues from Erwinaze and limit our potential future maintenance and growth of the market for this product. In addition, while we continue to work with the manufacturer of Erwinaze to evaluate potential steps to expand production capacity to increase the supply of Erwinaze over the longer term to address worldwide demand, our ability to maintain or increase sales of Erwinaze may be limited by our ability to obtain a sufficient supply of the product.
	In furtherance of our growth strategy, we have made a significant investment in Defitelio/defibrotide. We added the product to our portfolio as a result of our acquisition of Gentium that closed in January 2014, or the Gentium Acquisition, and secured worldwide rights to the product by acquiring rights to defibrotide in the Americas in August 2014. Our ability to realize the anticipated benefits from this investment is subject to a number of risks and uncertainties, including our ability to successfully maintain or grow sales of Defitelio in Europe, or obtain marketing approval in other countries, including the United States, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. We expect to continue to launch Defitelio in additional European countries on a rolling basis in 2015 and are in the process of making pricing and reimbursement submissions with respect to Defitelio, and discussing them with regulatory authorities, in those European countries where Defitelio is not yet launched, including in countries where pricing and reimbursement approvals are required for launch. A key challenge to our success in maintaining or growing sales of Defitelio in Europe is our ability to obtain appropriate pricing and reimbursement approvals in those European countries where Defitelio is not yet launched. If we experience delays or unforeseen difficulties in obtaining favorable pricing and reimbursement approvals, planned launches in the affected countries would be delayed, or, if we are unable to ultimately obtain favorable pricing and reimbursement approvals in countries that represent significant markets, especially where a country’s reimbursed price influences other countries, our growth prospects in Europe could be negatively affected.
	We are also engaged in activities related to the potential approval of defibrotide in the United States. We initiated a rolling submission of a new drug application, or NDA, to the FDA for defibrotide for the treatment of severe hepatic veno-occlusive disease, or VOD, in December 2014 and expect to complete the submission in mid-2015. We do not expect to be required to complete any additional clinical trials prior to completion of the NDA submission for defibrotide in the United States. Even if we are able to complete the NDA submission as planned, we cannot predict whether our NDA will be approved in a timely manner, if at all. It is possible that the FDA may ask an Oncologic Drugs Advisory Committee, or ODAC, which provides the FDA with independent expert advice and recommendations, to review our NDA. The ODAC may recommend against approval of our NDA, may recommend conditioning approval on our conducting one or more potentially time-consuming and costly clinical trials to provide supporting data either before approval or as a post-marketing commitment, or may recommend more narrow or restricted labeling than we expect to propose. We also face other challenges that could impact the anticipated value of Defitelio/defibrotide, including the limited size of the population of patients who undergo hematopoietic stem cell transplantation, or HSCT, therapy and develop severe VOD, the need to establish U.S. pricing and reimbursement support for the product in the event we are able to obtain U.S. marketing approval for defibrotide, the possibility that we may be required to conduct time-consuming and costly clinical trials as a condition of any U.S. marketing approval for the product, the lack of experience of U.S. physicians in diagnosing and treating VOD, and challenges to our ability to develop the product for indications in addition to the treatment of severe VOD. If sales of Defitelio/defibrotide do not reach the levels we expect, our anticipated revenue from the product would be negatively affected, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
	In addition to risks specifically related to Xyrem, Erwinaze and Defitelio/defibrotide, we are subject to other challenges and risks specific to our business, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including: the challenges of protecting and enhancing our intellectual property rights; delays or problems in the supply or manufacture of our products, particularly with respect to certain products as to which we maintain limited inventories, including products for which our supply demands are growing, and our dependence on single source suppliers to continue to meet our ongoing commercial demand or our requirements for clinical trial supplies; the need to obtain and maintain appropriate pricing and reimbursement for our products in an increasingly challenging environment due to, among other things, the attention being paid to healthcare cost containment and other austerity measures in the United States and worldwide, including the need to obtain and maintain reimbursement for Xyrem in the United States in an environment in which we are subject to increasingly restrictive conditions for reimbursement required by third party payors; and the challenges of compliance with the requirements of the FDA, the U.S. Drug Enforcement Administration, or DEA, and non-U.S. regulatory agencies, including with respect to product labeling, requirements for distribution, obtaining sufficient DEA quotas where needed, marketing and promotional activities, adverse event reporting and product recalls or withdrawals.
	Other risks and uncertainties related to our ability to execute on our strategy include: the challenges of achieving and maintaining commercial success of our products, such as obtaining sustained acceptance and support of our products by patients, physicians and payors; the risks and costs associated with business combination or product or product candidate acquisition transactions, such as the challenges inherent in the integration of acquired businesses with our historic business, the increase in geographic dispersion among our centers of operation, taking on the operation of a manufacturing plant as a result of the Gentium Acquisition and the risks that we may acquire unanticipated liabilities along with acquired businesses or otherwise fail to realize the anticipated benefits (commercial or otherwise) from such transactions; the difficulty and uncertainty of pharmaceutical product development, including the timing thereof, and the uncertainty of clinical success, such as the risk that results from preclinical studies and/or early clinical trials may not be predictive of results obtained in later and larger clinical trials planned or anticipated to be conducted for our product candidates; the inherent uncertainty associated with the regulatory approval process, especially as we continue to undertake increased activities and make growing investment in our product pipeline development projects; our potential inability to identify and acquire, in-license or develop additional products or product candidates to grow our business; and possible restrictions on our ability and flexibility to pursue certain future corporate development and other opportunities as a result of our substantial outstanding debt obligations, which increased significantly in 2014.
Concentrations of Risk	Concentrations of Risk
	Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities and issuers of investments to the extent recorded on the balance sheet.
	We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the United States, and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of March 31, 2015, five customers accounted for 87% of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliate CuraScript, Inc., or Express Scripts, which accounted for 69% of gross accounts receivable and IDIS Limited, or IDIS, which accounted for 9% of gross accounts receivable.  As of December 31, 2014, five customers accounted for 86% of gross accounts receivable, including Express Scripts, which accounted for 66% of gross accounts receivable and IDIS, which accounted for 11% of gross accounts receivable.
	We depend on single source suppliers and manufacturers for each of our products, product candidates and their active pharmaceutical ingredients.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.
Net Income per Ordinary Share Attributable to Jazz Pharmaceuticals plc	Net Income (Loss) Attributable to Jazz Pharmaceuticals plc per Ordinary Share
	Basic net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share is based on the weighted-average number of ordinary shares outstanding. Diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding.
	Basic and diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share were computed as follows (in thousands, except per share amounts):
		Three Months Ended
		March 31,
		2015			2014
	Numerator:
	Net income (loss) attributable to Jazz Pharmaceuticals plc	$	70,700		$	(92,650	)
	Denominator:
	Weighted-average ordinary shares used in calculating net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share - basic	60,803			58,526
	Dilutive effect of employee equity incentive and purchase plans	2,161			—
	Weighted-average ordinary shares used in calculating net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share - diluted	62,964			58,526
	Net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share:
	Basic	$	1.16		$	(1.58	)
	Diluted	$	1.12		$	(1.58	)
	For the three months ended March 31, 2014, potentially dilutive ordinary shares from employee equity incentive and purchase plans and warrants were not included in the diluted net loss attributable to Jazz Pharmaceuticals plc per ordinary share because the inclusion of such shares would have an anti-dilutive effect.
	Potentially dilutive ordinary shares from our employee equity incentive and purchase plans, warrants and exchangeable senior notes are determined by applying the treasury stock method to the assumed exercise of share options and warrants, the assumed vesting of outstanding restricted stock units, or RSUs, the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP, and the assumed issuance of ordinary shares upon exchange of our exchangeable senior notes. The potential issue of approximately 2.9 million ordinary shares issuable upon exchange of our exchangeable senior notes had no effect on diluted net income attributable to Jazz Pharmaceuticals plc per ordinary share because the average price of our ordinary shares for the three months ended March 31, 2015 did not exceed the effective exchange price of $199.77 per ordinary share.
	The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):
		Three Months Ended
		March 31,
		2015		2014
	1.875% exchangeable senior notes due 2021	2,878		—
	Options to purchase ordinary shares and RSUs	1,322		5,491
	Warrants to purchase ordinary shares	—		1,257
	Ordinary shares under ESPP	—		141
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In April 2015, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2015-03, “Interest - Imputation of Interest”, or ASU No. 2015-03. ASU No. 2015-03 requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the debt liability instead of as an asset. ASU No. 2015-03 does not affect the recognition and measurement guidance for debt issuance costs. ASU No. 2015-03 will be effective for us beginning January 1, 2016 and requires retrospective application. ASU-2015-03 will represent a change in accounting principle in 2016, the year of adoption. We are currently evaluating the impact of ASU 2015-03 on the presentation of our consolidated financial statements.
	In April 2015, the FASB issued ASU No. 2015-05, “Intangibles-Goodwill and Other-Internal-Use Software”, or ASU No. 2015-05. ASU No. 2015-05 provides guidance on whether a cloud computing arrangement contains a software license to be accounted for as internal-use software to assist in the evaluation of the accounting for fees paid by a customer in the arrangement. ASU No. 2015-05 will be effective for us beginning January 1, 2016 and may be applied either prospectively to new cloud computing arrangements or retrospectively. We are currently evaluating the impact of ASU 2015-05 on our consolidated financial statements.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers”, or ASU No. 2014-09, which states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this, an entity will need to identify the contract with a customer; identify the separate performance obligations in the contract; determine the transaction price; allocate the transaction price to the separate performance obligations in the contract; and recognize revenue when (or as) the entity satisfies each performance obligation. ASU No. 2014-09 will be effective for us beginning January 1, 2017 and can be adopted on a full retrospective basis or on a modified retrospective basis. We are currently assessing our approach to the adoption of this standard and the impact on our results of operations and financial position.

The_Company_and_Summary_of_Sig2

The Company and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basic and Diluted Net Income per Ordinary Share Computation	Basic and diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share were computed as follows (in thousands, except per share amounts):
		Three Months Ended
		March 31,
		2015			2014
	Numerator:
	Net income (loss) attributable to Jazz Pharmaceuticals plc	$	70,700		$	(92,650	)
	Denominator:
	Weighted-average ordinary shares used in calculating net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share - basic	60,803			58,526
	Dilutive effect of employee equity incentive and purchase plans	2,161			—
	Weighted-average ordinary shares used in calculating net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share - diluted	62,964			58,526
	Net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share:
	Basic	$	1.16		$	(1.58	)
	Diluted	$	1.12		$	(1.58	)
Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share	The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):
		Three Months Ended
		March 31,
		2015		2014
	1.875% exchangeable senior notes due 2021	2,878		—
	Options to purchase ordinary shares and RSUs	1,322		5,491
	Warrants to purchase ordinary shares	—		1,257
	Ordinary shares under ESPP	—		141

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents	Cash and cash equivalents consisted of the following (in thousands):
		31-Mar-15
		Amortized		Gross		Gross		Estimated		Cash and Cash Equivalents
		Cost		Unrealized		Unrealized		Fair Value
				Gains		Losses
	Cash	$	187,491	$	—	$	—	$	187,491	$	187,491
	Time deposits	595,112		—		—		595,112		595,112
	Totals	$	782,603	$	—	$	—	$	782,603	$	782,603
		31-Dec-14
		Amortized		Gross		Gross		Estimated		Cash and
		Cost		Unrealized		Unrealized		Fair Value		Cash
				Gains		Losses				Equivalents
	Cash	$	338,262	$	—	$	—	$	338,262	$	338,262
	Time deposits	345,780		—		—		345,780		345,780
	Totals	$	684,042	$	—	$	—	$	684,042	$	684,042
Available-for-Sale Securities and Other Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes, by major security type, our available-for-sale securities as of March 31, 2015 and December 31, 2014 that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands):
		31-Mar-15				31-Dec-14
		Significant Other		Total		Significant		Total
		Observable		Estimated		Other		Estimated
		Inputs		Fair Value		Observable		Fair Value
		(Level 2)				Inputs
						(Level 2)
	Time deposits	$	595,112	$	595,112	$	345,780	$	345,780

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Components of Inventories	Inventories consisted of the following (in thousands):
		March 31,		December 31,
		2015		2014
	Raw materials	$	2,358	$	3,570
	Work in process	13,319		9,870
	Finished goods	15,015		16,597
	Total inventories	$	30,692	$	30,037

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Gross Carrying Amount of Goodwill	The gross carrying amount of goodwill was as follows (in thousands):
	Balance at December 31, 2014	$	702,713
	Foreign exchange	(48,243		)
	Balance at March 31, 2015	$	654,470
Gross Carrying Amounts and Net Book Values of Intangible Assets	The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):
		March 31, 2015									December 31, 2014
		Remaining		Gross		Accumulated			Net Book		Gross		Accumulated			Net Book
		Weighted-		Carrying		Amortization			Value		Carrying		Amortization			Value
		Average Useful		Amount							Amount
		Life
		(In years)
	Acquired developed technologies	12.7		$	1,317,675	$	(256,258	)	$	1,061,417	$	1,450,606	$	(259,889	)	$	1,190,717
	Manufacturing contracts	2.8		11,616		(3,458		)	8,158		13,012		(3,060		)	9,952
	Trademarks	—		2,880		(2,880		)	—		2,914		(2,896		)	18
	Total finite-lived intangible assets			1,332,171		(262,596		)	1,069,575		1,466,532		(265,845		)	1,200,687
	Acquired IPR&D assets			214,733		—			214,733		236,748		—			236,748
	Total intangible assets			$	1,546,904	$	(262,596	)	$	1,284,308	$	1,703,280	$	(265,845	)	$	1,437,435
Estimated Future Amortization Costs	Based on finite-lived intangible assets recorded as of March 31, 2015, and assuming the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands):
	Year Ending December 31,	Estimated
		Amortization
		Expense
	2015 (remainder)	$	70,507
	2016	90,688
	2017	90,688
	2018	87,168
	2019	86,952
	Thereafter	643,572
	Total	$	1,069,575

Certain_Balance_Sheet_Items_Ta

Certain Balance Sheet Items (Tables)	3 Months Ended
	Mar. 31, 2015
Certain Balance Sheet Items [Abstract]
Property and Equipment	Property and equipment consisted of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Construction-in-progress	$	49,447		$	37,145
	Computer software	12,460			10,634
	Computer equipment	8,754			7,670
	Leasehold improvements	8,191			7,931
	Machinery and equipment	5,804			6,408
	Furniture and fixtures	2,171			2,220
	Land and buildings	1,380			1,547
	Subtotal	88,207			73,555
	Less accumulated depreciation and amortization	(16,924		)	(15,192		)
	Property and equipment, net	$	71,283		$	58,363
Accrued Liabilities	Accrued liabilities consisted of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Rebates and other sales deductions	$	58,003		$	51,899
	Employee compensation and benefits	27,707			46,143
	Sales returns reserve	10,777			14,039
	Accrued interest	7,637			10,327
	Royalties	7,158			7,964
	Accrued construction-in-progress	6,050			4,931
	Professional fees	3,726			3,295
	Other	25,917			25,493
	Total accrued liabilities	$	146,975		$	164,091

Debt_Tables

Debt (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of Long-term Debt	The following table summarizes the carrying amount of our indebtedness (in thousands):
		March 31,			December 31,
		2015			2014
	1.875% exchangeable senior notes due 2021	$	575,000		$	575,000
	Unamortized discount on 1.875% exchangeable senior notes due 2021	(120,985		)	(124,735		)
	1.875% exchangeable senior notes due 2021, net	454,015			450,265
	Term loans	888,550			890,479
	Other borrowings	1,484			1,684
	Total debt	1,344,049			1,342,428
	Less current portion	9,388			9,428
	Total long-term debt	$	1,334,661		$	1,333,000
Schedule of Maturities of Long-Term Debt	Scheduled maturities with respect to our long-term debt are as follows (in thousands):
	Year Ending December 31,	Scheduled Long-Term Debt Maturities
	2015 (remainder)	$	7,106
	2016	9,391
	2017	9,396
	2018	868,452
	2019	101
	Thereafter	575,134
	Total	$	1,469,580

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments under Noncancelable Operating Leases	Future minimum lease payments under our noncancelable operating leases at March 31, 2015 were as follows (in thousands):
	Year Ending December 31,	Lease
		Payments
	2015 (remainder)	$	7,422
	2016	7,609
	2017	7,137
	2018	7,831
	2019	7,145
	Thereafter	73,265
	Total	$	110,409

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Summary of stockholders equity	The following tables present a reconciliation of our beginning and ending balances in shareholders’ equity for the three months ended March 31, 2015 and 2014, respectively (in thousands):
		Attributable to:
		Jazz Pharmaceuticals plc			Noncontrolling interests			Total Shareholders' Equity
	Shareholders' equity at January 1, 2015	$	1,371,144		$	64		$	1,371,208
	Issuance of ordinary shares in conjunction with employee equity incentive plans	13,504			—			13,504
	Employee withholding taxes related to share-based awards	(14,778		)	—			(14,778		)
	Share-based compensation	20,896			—			20,896
	Tax benefit from employee share options	10,635			—			10,635
	Shares repurchased	(10,338		)	—			(10,338		)
	Other comprehensive loss	(156,487		)	(10		)	(156,497		)
	Net income	70,700			—			70,700
	Shareholders' equity at March 31, 2015	$	1,305,276		$	54		$	1,305,330
		Attributable to:
		Jazz Pharmaceuticals plc			Noncontrolling interests			Total Shareholders' Equity
	Shareholders' equity at January 1, 2014	$	1,295,534		$	—		$	1,295,534
	Noncontrolling interests from the Gentium Acquisition	—			136,578			136,578
	Acquisition of noncontrolling interests	(924		)	(118,251		)	(119,175		)
	Issuance of ordinary shares in conjunction with employee equity incentive plans and warrant exercises	21,467			—			21,467
	Employee withholding taxes related to share-based awards	(9,363		)	—			(9,363		)
	Share-based compensation	14,313			—			14,313
	Tax benefit from employee share options	5,777			—			5,777
	Other comprehensive income	14,739			277			15,016
	Net loss	(92,650		)	(989		)	(93,639		)
	Shareholders' equity at March 31, 2014	$	1,248,893		$	17,615		$	1,266,508
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss attributable to Jazz Pharmaceuticals plc as of March 31, 2015 and December 31, 2014 were as follows (in thousands):
		Foreign			Total
		Currency			Accumulated
		Translation			Other
		Adjustments			Comprehensive
					Loss
	Balance at December 31, 2014	$	(122,097	)	$	(122,097	)
	Other comprehensive loss	(156,487		)	(156,487		)
	Balance at March 31, 2015	$	(278,584	)	$	(278,584	)

Segment_and_Other_Information_

Segment and Other Information (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Summary of Total Revenues	The following table presents a summary of total revenues (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Xyrem® (sodium oxybate) oral solution	$	212,690		$	160,378
	Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi)	50,353			46,920
	Defitelio® (defibrotide)/defibrotide	17,363			12,209
	Prialt® (ziconotide) intrathecal infusion	6,764			4,309
	Psychiatry	9,093			9,866
	Other	10,772			11,304
	Product sales, net	307,035			244,986
	Royalties and contract revenues	2,268			1,933
	Total revenues	$	309,303		$	246,919
Summary of Total Revenues Attributed to Geographic Sources	The following table presents a summary of total revenues attributed to geographic sources (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	United States	$	269,247		$	214,956
	Europe	32,635			24,343
	All other	7,421			7,620
	Total revenues	$	309,303		$	246,919
Summary of Revenues from Customers Representing More Than 10% of Total Revenues	The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:
		Three Months Ended
		March 31,
		2015		2014
	Express Scripts	69	%	65	%
	Accredo Health Group, Inc.	13	%	15	%
Total Long-Lived Assets by Location	The following table presents total long-lived assets, consisting of property and equipment, by location (in thousands):
		March 31,			December 31,
		2015			2014
	Ireland	$	50,190		$	37,775
	United States	10,963			9,795
	Italy	7,767			8,462
	Other	2,363			2,331
	Total long-lived assets	$	71,283		$	58,363

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation Expense	Share-based compensation expense related to share options, RSUs and grants under our ESPP was as follows (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Selling, general and administrative	$	16,639		$	11,175
	Research and development	3,485			2,459
	Cost of product sales	695			181
	Total share-based compensation expense, pre-tax	20,819			13,815
	Tax benefit from share-based compensation expense	(6,154		)	(4,286		)
	Total share-based compensation expense, net of tax	$	14,665		$	9,529
Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model which was Used to Estimate Grant Date Fair Value per Share	The table below shows the number of shares underlying options granted to purchase our ordinary shares, the weighted-average assumptions used in the Black-Scholes option pricing model and the resulting weighted-average grant date fair value of share options granted:
		Three Months Ended
		March 31,
		2015			2014
	Shares underlying options granted (in thousands)	880			706
	Grant date fair value	$	57.49		$	63.08
	Black-Scholes option pricing model assumption information:
	Volatility	39		%	46		%
	Expected term (years)	4.2			4.3
	Range of risk-free rates	1.1-1.3%			1.1-1.2%
	Expected dividend yield	—		%	—		%
Schedule of Restricted Stock Unit activity	The table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted:
		Three Months Ended
		March 31,
		2015			2014
	RSUs granted (in thousands)	338			341
	Grant date fair value	$	174.56		$	165.61

Restructuring_Tables

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2015
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	The following table summarizes the amounts related to restructuring through March 31, 2015 (in thousands):
		Termination Benefits			Facility Closure Costs			Total
	Balance at December 31, 2014	$	1,823		$	118		$	1,941
	Costs incurred during the period	371			182			553
	Cash payments	(1,756		)	(117		)	(1,873		)
	Balance at March 31, 2015	$	438		$	183		$	621

The_Company_and_Summary_of_Sig3

The Company and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, except Share data in Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Aug. 31, 2014
	Customer		Customer
Summary Of Significant Accounting Policies [Line Items]
Product sales, net	$307,035	$244,986
Number of customers with significant accounts receivable	5		5
Percentage of gross accounts receivable	87.00%		86.00%
Express Scripts [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of gross accounts receivable	69.00%		66.00%
Idis Limited [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of gross accounts receivable	9.00%		11.00%
Xyrem [Member]
Summary Of Significant Accounting Policies [Line Items]
Product sales, net	212,690	160,378
Number of ANDAs filed by third parties	5
Erwinaze And Erwinase [Member]
Summary Of Significant Accounting Policies [Line Items]
Product sales, net	$50,353	$46,920
Sales Revenue, Product Line [Member] | Product Concentration Risk [Member] | Xyrem [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of product sales, net	69.30%
Sales Revenue, Product Line [Member] | Product Concentration Risk [Member] | Erwinaze And Erwinase [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of product sales, net	16.40%
Convertible Debt [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of shares issuable from exchangeable senior notes	2.9
Debt conversion price (in dollars per share)				$199.77
Interest rate	1.88%		1.88%
Pending Litigation [Member] | Xyrem [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of lawsuits filed	5

Basic_and_Diluted_Net_Income_L

Basic and Diluted Net Income (Loss) per Common Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Numerator:
Net income (loss) attributable to Jazz Pharmaceuticals plc	$70,700	($92,650)
Denominator:
Weighted-average ordinary shares used in calculating net income (loss) per ordinary share attributable to Jazz Pharmaceuticals plc - basic (in shares)	60,803	58,526
Dilutive effect of employee equity incentive and purchase plans (in shares)	2,161	0
Weighted-average ordinary shares - diluted (in shares)	62,964	58,526
Net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share:
Basic net income (in dollars per share)	$1.16	($1.58)
Diluted net income (in dollars per share)	$1.12	($1.58)

WeightedAverage_Ordinary_Share

Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares	2,878	0
Equity Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares	1,322	5,491
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares	0	1,257
Ordinary shares under ESPP [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares	0	141
Convertible Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Interest rate	1.88%		1.88%

Disposition_Additional_Informa

Disposition - Additional Information (Details) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 20, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net proceeds from sale of business	$32,703,000	$0
Certain EUSA Products [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration			34,000,000
Net proceeds from sale of business			33,000,000
Selling, general and administrative [Member] | Certain EUSA Products [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on disposal	$200,000

Summary_of_Cash_and_Cash_Equiv

Summary of Cash and Cash Equivalents (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Cash and cash equivalents [Line Items]
Amortized Cost	$782,603	$684,042
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	782,603	684,042
Cash and cash equivalents	782,603	684,042	245,874	636,504
Cash [Member]
Cash and cash equivalents [Line Items]
Amortized Cost	187,491	338,262
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	187,491	338,262
Cash and cash equivalents	187,491	338,262
Time deposits [Member]
Cash and cash equivalents [Line Items]
Amortized Cost	595,112	345,780
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	595,112	345,780
Cash and cash equivalents	$595,112	$345,780

Fair_Value_Measurement_Availab

Fair Value Measurement Available-For-Sale Investments Measured at Fair Value on Recurring Basis (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Estimated Fair Value	$782,603	$684,042
Time deposits [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Estimated Fair Value	595,112	345,780
Fair Value, Measurements, Recurring [Member] | Time deposits [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Estimated Fair Value	595,112	345,780
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Time deposits [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Estimated Fair Value	$595,112	$345,780

Fair_Value_Additional_Informat

Fair Value - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Fair Value Measurements [Line Items]
Long-term Debt	$1,344,049,000	$1,342,428,000
Principal amount	1,469,580,000
Assets held for sale	0	32,833,000
Term Loans [Member]
Fair Value Measurements [Line Items]
Fair value of term loan	893,000,000
Long-term Debt	888,600,000
Principal amount	893,100,000
Convertible Debt [Member]
Fair Value Measurements [Line Items]
Long-term Debt	454,015,000	450,265,000
Principal amount	575,000,000	575,000,000
Fair value of exchangeable senior notes	669,000,000
Certain EUSA Products [Member]
Fair Value Measurements [Line Items]
Assets held for sale		$32,800,000

Components_of_Inventories_Deta

Components of Inventories (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$2,358	$3,570
Work in process	13,319	9,870
Finished goods	15,015	16,597
Total inventories	$30,692	$30,037

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Goodwill [Roll Forward]
Goodwill, beginning of period	$702,713
Foreign exchange	-48,243
Goodwill, end of period	$654,470

Gross_Carrying_Amounts_and_Net

Gross Carrying Amounts and Net Book Values of Intangible Assets (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount - Finite-Lived Intangible Assets	$1,332,171	$1,466,532
Accumulated Amortization - Finite-Lived Intangible Assets	-262,596	-265,845
Total	1,069,575	1,200,687
Gross Carrying Amount - Total Intangible Assets	1,546,904	1,703,280
Net Book Value - Total Intangible Assets	1,284,308	1,437,435
Acquired IPR&D assets [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
In-process research and development	214,733	236,748
Acquired developed technologies [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	12 years 8 months
Gross Carrying Amount - Finite-Lived Intangible Assets	1,317,675	1,450,606
Accumulated Amortization - Finite-Lived Intangible Assets	-256,258	-259,889
Total	1,061,417	1,190,717
Manufacturing Contracts [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	2 years 10 months
Gross Carrying Amount - Finite-Lived Intangible Assets	11,616	13,012
Accumulated Amortization - Finite-Lived Intangible Assets	-3,458	-3,060
Total	8,158	9,952
Trademarks [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	0 years
Gross Carrying Amount - Finite-Lived Intangible Assets	2,880	2,914
Accumulated Amortization - Finite-Lived Intangible Assets	-2,880	-2,896
Total	$0	$18

Estimated_Future_Amortization_

Estimated Future Amortization Costs (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Estimated Amortization Expense
2015 (remainder)	$70,507
2016	90,688
2017	90,688
2018	87,168
2019	86,952
Thereafter	643,572
Total	$1,069,575	$1,200,687

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Certain Balance Sheet Items [Abstract]
Construction-in-progress	$49,447	$37,145
Computer software	12,460	10,634
Computer equipment	8,754	7,670
Leasehold improvements	8,191	7,931
Machinery and equipment	5,804	6,408
Furniture and fixtures	2,171	2,220
Land and buildings	1,380	1,547
Subtotal	88,207	73,555
Less accumulated depreciation and amortization	-16,924	-15,192
Property and equipment, net	$71,283	$58,363

Accrued_Liabilities_Detail

Accrued Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Certain Balance Sheet Items [Abstract]
Rebates and other sales deductions	$58,003	$51,899
Employee compensation and benefits	27,707	46,143
Sales returns reserve	10,777	14,039
Accrued interest	7,637	10,327
Royalties	7,158	7,964
Accrued construction-in-progress	6,050	4,931
Professional fees	3,726	3,295
Other	25,917	25,493
Total accrued liabilities	$146,975	$164,091

Schedule_of_Debt_Details

Schedule of Debt (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Principal amount	$1,469,580
Total debt	1,344,049	1,342,428
Less current portion	9,388	9,428
Total long-term debt	1,334,661	1,333,000
Convertible Debt 2021 Notes [Member]
Debt Instrument [Line Items]
Interest rate	1.88%	1.88%
Principal amount	575,000	575,000
Unamortized discount	-120,985	-124,735
Total debt	454,015	450,265
Term Loans [Member]
Debt Instrument [Line Items]
Interest rate	3.25%
Total debt	888,550	890,479
Other borrowings [Member]
Debt Instrument [Line Items]
Total debt	$1,484	$1,684

Schedule_of_Maturities_Details

Schedule of Maturities (Details) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Long-term Debt, Fiscal Year Maturity [Abstract]
2015 (remainder)	$7,106
2016	9,391
2017	9,396
2018	868,452
2019	101
Thereafter	575,134
Total debt	$1,469,580

Debt_Additional_Information_De

Debt - Additional Information (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Principal amount	$1,469,580,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Undrawn revolving credit facilities amount	425,000,000
Letter of Credit [Member]
Debt Instrument [Line Items]
Undrawn revolving credit facilities amount	1,100,000
Term Loans [Member]
Debt Instrument [Line Items]
Principal amount	893,100,000
Convertible Debt 2021 Notes [Member]
Debt Instrument [Line Items]
Principal amount	575,000,000	575,000,000
Interest rate	1.88%	1.88%
Carrying value of the equity component	$126,900,000
Term Loans [Member]
Debt Instrument [Line Items]
Interest rate	3.25%
Effective interest rate	4.10%

Future_Minimum_Lease_Payments_

Future Minimum Lease Payments under Noncancelable Operating Leases (Detail) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Lease Payments
2015 (remainder)	$7,422
2016	7,609
2017	7,137
2018	7,831
2019	7,145
Thereafter	73,265
Total	$110,409

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)

3 Months Ended

0 Months Ended

26 Months Ended

23 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Mar. 31, 2015

Feb. 20, 2015

Jan. 08, 2015

Dec. 11, 2014

Oct. 02, 2014

Jul. 15, 2014

20-May-14

Dec. 27, 2013

Nov. 21, 2013

Jan. 18, 2013

Dec. 10, 2012

Nov. 22, 2010

Oct. 18, 2010

Dec. 05, 2012

Jul. 23, 2010

Jan. 31, 2015

Aug. 31, 2014

Apr. 30, 2015

Dec. 31, 2014

Nov. 25, 2008

Oct. 19, 2011

Jan. 31, 2014

product

patent

patent

patent

patent

patent

patent

patent

patent

patent

patent

patent

patent

patent

renewal_term

lawsuit

Commitments and Contingencies Disclosure [Line Items]

Total future lease payments

$110,409,000

Construction-in-progress

49,447,000

37,145,000

Other non-current liabilities

45,122,000

38,393,000

Noncancelable purchase commitments, due within one year

27,400,000

Number of radiopharmaceutical products

2

Xyrem ANDA Matters [Member] | Pending Litigation [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of patents allegedly infringed upon

3

3

15

2

14

4

13

9

5

10

Court ordered stay period

30 months

30 months

30 months

FazaClo ANDA Matters [Member] | Pending Litigation [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of ANDAs filed by 3rd parties

3

Number of ANDAs outstanding

2

FazaClo [Member] | Pending Litigation [Member]

Commitments and Contingencies Disclosure [Line Items]

Amounts sought in alleged breach of contractual obligations - minimum

10,500,000

Amounts sought in alleged breach of contractual obligations - additional

25,000,000

Gentium [Member] | Pending Litigation [Member]

Commitments and Contingencies Disclosure [Line Items]

Share price (in dollars per share)

$57

Xyrem [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of ANDAs outstanding

5

Xyrem [Member] | Pending Litigation [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of patents named in CBM petitions

6

6

Palo Alto [Member] | Building [Member]

Commitments and Contingencies Disclosure [Line Items]

Operating lease, term (in years)

12 years

Number of renewal option terms

2

Operating lease, extended term option (in years)

5 years

Total future lease payments

88,000,000

Rent expense

400,000

Palo Alto [Member] | Building [Member] | Property and Equipment, Net [Member]

Commitments and Contingencies Disclosure [Line Items]

Construction-in-progress

1,000,000

Palo Alto [Member] | Building [Member] | Other Non-Current Liabilities [Member]

Commitments and Contingencies Disclosure [Line Items]

Other non-current liabilities

1,000,000

Subsequent Event [Member] | Palo Alto [Member] | Building [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of renewal option terms

2

Operating lease, extended term option (in years)

1 year

Total future lease payments

$10,000,000

Share_Repurchase_Program_Detai

Share Repurchase Program (Detail) (Ordinary Options [Member], USD $)	3 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Mar. 31, 2015	31-May-13
Ordinary Options [Member]
Stock Activity [Line Items]
Total amount authorized for repurchase of shares under share repurchase program		$200,000,000
Shares repurchased	10,300,000
Shares repurchased (in shares)	0.1
Average price of shares repurchased (in dollars per share)	$164.54
Remaining amount authorized for repurchase of shares	$11,000,000

Shareholders_Equity_Details

Shareholders Equity (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders equity, beginning of period	$1,371,208	$1,295,534
Noncontrolling interests from the Gentium Acquisition		136,578
Acquisition of noncontrolling interests		-119,175
Issuance of ordinary shares in conjunction with employee equity incentive plans and warrant exercises	13,504	21,467
Employee withholding taxes related to share-based awards	-14,778	-9,363
Share-based compensation	20,896	14,313
Tax benefit from employee share options	10,635	5,777
Shares repurchased	-10,338
Other comprehensive income (loss)	-156,497	15,016
Net income (loss)	70,700	-93,639
Shareholders equity, end of period	1,305,330	1,266,508
Parent [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders equity, beginning of period	1,371,144	1,295,534
Noncontrolling interests from the Gentium Acquisition		0
Acquisition of noncontrolling interests		-924
Issuance of ordinary shares in conjunction with employee equity incentive plans and warrant exercises	13,504	21,467
Employee withholding taxes related to share-based awards	-14,778	-9,363
Share-based compensation	20,896	14,313
Tax benefit from employee share options	10,635	5,777
Shares repurchased	-10,338
Other comprehensive income (loss)	-156,487	14,739
Net income (loss)	70,700	-92,650
Shareholders equity, end of period	1,305,276	1,248,893
Noncontrolling Interest [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders equity, beginning of period	64	0
Noncontrolling interests from the Gentium Acquisition		136,578
Acquisition of noncontrolling interests		-118,251
Other comprehensive income (loss)	-10	277
Net income (loss)	0	-989
Shareholders equity, end of period	$54	$17,615

Component_of_Accumulated_Other

Component of Accumulated Other Comprehensive Loss (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2014	($122,097)
Other comprehensive loss	-156,497	15,016
Balance at March 31, 2015	-278,584
Foreign Currency Translation Adjustments [Member]
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2014	-122,097
Other comprehensive loss	-156,487
Balance at March 31, 2015	-278,584
Parent [Member]
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2014	-122,097
Other comprehensive loss	-156,487
Balance at March 31, 2015	($278,584)

Segment_and_Other_Information_1

Segment and Other Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
	Segment
Segment Reporting [Abstract]
Number of operating business segment	1

Summary_of_Total_Revenues_Deta

Summary of Total Revenues (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenue from External Customer [Line Items]
Product sales, net	$307,035	$244,986
Royalties and contract revenues	2,268	1,933
Total revenues	309,303	246,919
Xyrem [Member]
Revenue from External Customer [Line Items]
Product sales, net	212,690	160,378
Erwinaze And Erwinase [Member]
Revenue from External Customer [Line Items]
Product sales, net	50,353	46,920
Defitelio [Member]
Revenue from External Customer [Line Items]
Product sales, net	17,363	12,209
Prialt [Member]
Revenue from External Customer [Line Items]
Product sales, net	6,764	4,309
Psychiatry [Member]
Revenue from External Customer [Line Items]
Product sales, net	9,093	9,866
Other [Member]
Revenue from External Customer [Line Items]
Product sales, net	$10,772	$11,304

Summary_of_Total_Revenues_Attr

Summary of Total Revenues Attributed to Geographic Sources (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$309,303	$246,919
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	269,247	214,956
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	32,635	24,343
All Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$7,421	$7,620

Summary_of_Revenues_from_Custo

Summary of Revenues from Customers Representing at Least 10% of Total Revenues (Detail) (Sales Revenue, Goods, Net [Member])	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Express Scripts [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenues	69.00%	65.00%
Accredo Health Group, Inc. [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenues	13.00%	15.00%

Total_LongLived_Assets_by_Loca

Total Long-Lived Assets by Location (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]
Property and equipment, net	$71,283	$58,363
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property and equipment, net	50,190	37,775
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property and equipment, net	10,963	9,795
Italy [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property and equipment, net	7,767	8,462
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property and equipment, net	$2,363	$2,331

ShareBased_Compensation_Expens

Share-Based Compensation Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$20,819	$13,815
Tax benefit from share-based compensation expense	-6,154	-4,286
Total share-based compensation expense, net of tax	14,665	9,529
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	16,639	11,175
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	3,485	2,459
Cost of product sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$695	$181

WeightedAverage_Assumptions_an

Weighted-Average Assumptions and Resulting Grant Date Fair Value (Detail) (Employee Stock Option [Member], USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Stock Option [Member]
Schedule of Weighted Average Assumptions for Fair Values of Stock Options[Line Items]
Shares underlying options granted (in shares)	880	706
Weighted-average grant date fair value (in dollars per share)	$57.49	$63.08
Weighted-average volatility	39.00%	46.00%
Weighted-average expected term (years)	4 years 2 months 24 days	4 years 3 months 24 days
Range of risk-free rates, minimum	1.10%	1.10%
Range of risk-free rates, maximum	1.30%	1.20%
Expected dividend yield	0.00%	0.00%

ShareBased_Compensation_Restri

Share-Based Compensation Restricted Units (Details) (Restricted Stock Units (RSUs) [Member], USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Units granted	338	341
Weighted average grand date fair value (in dollars per share)	$174.56	$165.61

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested stock option and RSUs	$98.80
Weighted-average period expected to be recognized	2 years 8 months 14 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Unrecognized compensation cost related to unvested stock option and RSUs	$109.60
Weighted-average period expected to be recognized	2 years 7 months 24 days

Restructuring_Details

Restructuring (Details) (USD $)	3 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Restructuring Reserve [Roll Forward]
Cash payments	($1,873)
One-time Termination Benefits [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period		2,200
Cash payments	-1,756
Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period		300
Cash payments	-117
Selling, general and administrative [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period	553
Selling, general and administrative [Member] | One-time Termination Benefits [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period	371
Selling, general and administrative [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period	182
Accrued Liabilities [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning of period			1,941
Balance, end of period	621	621	1,941
Accrued Liabilities [Member] | One-time Termination Benefits [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning of period			1,823
Balance, end of period	438	438	1,823
Accrued Liabilities [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning of period			118
Balance, end of period	$183	$183	$118

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Taxes [Line Items]
Income tax provision	$32,059	$17,027
Effective income tax rate, percentage	31.20%	33.80%
Acquired in-process research and development	$0	$127,000
Ireland [Member]
Income Taxes [Line Items]
Effective statutory income tax rate, percentage	12.50%